Phase II Annual Planner 2024-25
MONTH | DAY | 8 - 11 am | 11-12 pm | Lunch 12-1 pm | 1-2 pm | 2-3 pm | 3-4 pm | ||
---|---|---|---|---|---|---|---|---|---|
FIRST MONTH | DAY 1 | CLINICAL POSTING | IM 8.31.SYSTEMIC HYPERTENSION | PH 1.1 PRINCIPLES OF PHARMACOLOGY AND PHARMACOTHERAPEUTICS | MI 1.1 INTRO AND MORPHOLOGY OF BACTERIA | FM 1.1 BASICS OF FORENSIC MEDICINE | |||
DAY 2 | CLINICAL POSTING | SU 1.1 Basic Concept of hemostasis, metabolic changes in injury & their mediators. | PATH 1.1,1.2,1.3 INTRODUCTION TO PATHOLOGY | MI 1.1 INTRO AND MORPHOLOGY OF BACTERIA | MI 1.2 MICROSCOPY - DOAP | ||||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.4 ABSORPTION, DISTRIBUTION (SGD) | PA 2.4 CELL DEATH NECROSIS (SGD) | DOAP PATH 1.1,1.2,1.3 INTRODUCTION TO PATHOLOGY | ||||
DAY 4 | CLINICAL POSTING | 2.2 CM 7.7, 8.4, 8.5 INVESTIGATION, PREVENTION AND CONTROL STRATEGIES FOR EMERGING AND RE-EMERGING INFECTIOUS DISEASES AT COMMUNITY LEVEL | MI 1.1 CULTURE MEDIA AND METHODS9(SGD) | PA 2.4 CELL DEATH APOPTOSIS (SGD) | PH 1.3,1.11- ROUTES OF DRUG ADMINISTRATION, DRUG DELIVERY SYSTEM AND FORMULATIONS (DOAP) | ||||
DAY 5 | CLINICAL POSTING | 2.3 Sample collection procedures I (SGD) | PA 2.1, 2.2 CELL INJURY PA 2.3 INTRACELLULAR ACCUMULATIONS (SGD) | DOAP - PH 1.3,1.11- ROUTES OF DRUG ADMINISTRATION, DRUG DELIVERY SYSTEM AND FORMULATIONS | DOAP - PH 4.1 ADMINISTER DRUGS THROUGH VARIOUS ROUTES IN A SIMULATED ENVIRONMENT USING MANNEQUINES | ||||
DAY 6 | CLINICAL POSTING | AETCOM MODULE 2.5 IDENTY, DISCUSS AND DEFINED MEDICO - LEGAL, SOCIO - LEGAL, SOCIO - CULTURAL AND ETHICAL ISSUES AS IT PERTAINS TO PATIENT AUTONOMY, PATIENT RIGHTS AND SHARED RESPONSIBILITY IN HEALTH CARE | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 2.1 ACUTE MYOCARDIAL INFARCTION/IHD | PH 2.1 UNDERSTANDING OF THE USE OF VARIOUS DOSAGE FORMS | MI 1.1 INTRODUCTION TO VIROLOGY AND DIAGNOSTIC METHODS | FM 1.1 BASICS OF CLINICAL FORENSIC MEDICINE | ||||
DAY 2 | CLINICAL POSTING | SU 1.2 Factors affecting metabolic response to injury | PA 2.5, 2.7-PATHOLOGICAL CALCIFICATION, GANGRENE, CELLULAR AGEING (SGD) | MI 1.1 INTRODUCTION TO PARASITOLOGY AND DIAGNOSTIC METHODS | MI 1.2 GRAM STAIN - DOAP | ||||
DAY 3 | CLINICAL POSTING | 2.2 CM 8.1 EPIDEMIOLOGY OF H1N1 INFLUENZA AND COVID 19 PANDEMIC (SGD) | PH 1.4 METABOLISM (SGD) | 2.6 CELLULAR ADAPTATIONS (SGD) | DOAP PATH 2.8 VARIOUS FORMS OF CELL INJURY | ||||
DAY 4 | CLINICAL POSTING | 2.2 CM 8.1 EPIDEMIOLOGY OF EBOLA AND NIPAH VIRUS DISEASE (SGD) | MI 1.1 BACTERIOPHAGE, VIRUS HOST INTERACTION | PA 4.1 GENERAL FEATURES OF ACUTE AND CHRONIC INFLAMMATION | PH 1.4 EXCRETION OF DRUGS (SGD) | ||||
DAY 5 | CLINICAL POSTING | 2.3 Sample collection procedures II(SGD) | 4.2 MEDIATORS OF ACUTE INFLAMMATION (SGD) | SGD PH1.9,1.11 NOMENCLATURE OF DRUGS, SOURCES OF DRUGS, ROUTES OF DRUG ADMINISTRATION | SGD PH 1.9,1.11 NOMENCLATURE OF DRUGS, ROUTES OF DRUG ADMINISTRATION | ||||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 1.1 HEART FAILURE | PH 1.4 EXCRETION OF DRUGS (SGD) | MI 1.1 BACTERIOPHAGE, VIRUS HOST INTERACTION | FM 1.1 BASICS OF FORENSIC PATHOLOGY,STATE MEDICINE | ||||
DAY 2 | CLINICAL POSTING | P 4.3 CHRONIC INFLAMMATION (SGD), SYSTEMIC EFFECTS OFINFLAMMATION | P 4.3 CHRONIC INFLAMMATION (SGD), SYSTEMIC EFFECTS OFINFLAMMATION | MI 1.1 INTRODUCTION TO PARASITOLOGY AND DIAGNOSTIC METHODS | MI 1.2 GRAM STAIN - DOAP | ||||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.2 EVIDENCE BASED MEDICINE , THERAPEUTIC DRUG MONITORING | PA 3.1 AMYLOIDOSIS (SGD) | DOAP PATH 2.8 VARIOUS FORMS OF CELL INJURY | ||||
DAY 4 | CLINICAL POSTING | 2.2 CM 7.7, 8.4, 8.5 INVESTIGATION, PREVENTION AND CONTROL STRATEGIES FOR EBOLA AND NIPAH VIRUS DISEASE AT COMMUNITY LEVEL | 1.1 INTRODUCION TO MYCOLOGY AND DIAGNOSTIC METHODS | PA 5.1 PROCESS OF REPAIR AND REGENERATION (SGD) | PH 1.5 MECHANISM OF DRUG ACTION (SGD) | ||||
DAY 5 | CLINICAL POSTING | 2.3 Microbial diagnosis I(SGD) | 6.1, 6.2 EDEMA, HYPEREMIA, CONGESTION, HEMORRHAGE (SGD) | SGD PH 2.1 DEMONSTRATE UNDERSTANDING THE USE OF VARIOUS DOSAGE FORMS (ORAL/LOCAL/PARENTERAL; SOLID/LIQUID) | SGD PH 2.1 DEMONSTRATE UNDERSTANDING THE USE OF VARIOUS DOSAGE FORMS (ORAL/LOCAL/PARENTERAL; SOLID/LIQUID) | ||||
DAY 6 | CLINICAL POSTING | AT COM Module - 2.1, DEMONSTRATE ABILITY TO COMMUNICATE TO PATIENT IN A PATIENT, RESPECTFUL, NON THREATENING, NON JUDGEMENTAL AND EMPATHETIC MANNER | SPORTS AND EXTRA CURRICULAR ACTIVITY | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 3.1 PNEUMONIA | PH 1.5 MECHANISM OF DRUG ACTION (SGD) | 1.1Bacterial genetics | FM 1.1 BASICS OF LEGAL MEDICINE | ||||
DAY 2 | CLINICAL POSTING | SU 2.1 Pathophysiology of Shocks types of shocks, principles of resuscitation fluid replacement & monitoring | PA 6.3 SHOCK (SGD) | MI 1.1 NORMAL FLORA(SDL) | MI 1.2 GRAM STAIN - DOAP | ||||
DAY 3 | CLINICAL POSTING | 2.4 CM 10.5 UNIVERSAL IMMUNIZATION PROGRAMME - COLD CHAIN, MICROPLANNING, VACCINATION SCHEDULE, ROUTINE AND SUPPLEMENTARY IMMUNIZATION | PA 6.4 NORMAL HEMOSTASIS AND THROMBOSIS (SDL) | DOAP PATH - CHRONIC INFLAMMATION | |||||
DAY 4 | CLINICAL POSTING | 2.4 CM 8.5, 8.6 PLANNING, IMPLEMENTING AND EVALUATING VACCINATION PROGRAMME DURING PANDEMIC | MI 1.1 MICROBIAL PATHOGENECITY | PA 6.5, 6.6 EMBOLISM, ISCHEMIA, INFARCTION (SGD) | PH 1.60 PHARMACOGENOMICS | ||||
DAY 5 | CLINICAL POSTING | 2.3 Microbial diagnosis II(SGD) | PA 7.1 DEFINE AND CLASSIFY NEOPLASIA- BENIGN AND MLIGNANT, EPIDEMIOLOGY OF CANCER (SGD) | SGD PH 2.4 DEMONSTRATE THE CORRECT METHOD OF CALCULATION OF DRUG DOSAGE IN PATIENTS INCLUDING THOSE USED IN SPECIAL SITUATIONS | SGD PH 2.4 DEMONSTRATE THE CORRECT METHOD OF CALCULATION OF DRUG DOSAGE IN PATIENTS INCLUDING THOSE USED IN SPECIAL SITUATIONS | ||||
DAY 6 | CLINICAL POSTING | 2.1 Infection Control Practices - Airborne precautions, Contact Precuations, Infection Control Committee | |||||||
DAY 7 | |||||||||
SECOND MONTH | DAY 1 | CLINICAL POSTING | IM 9.1 ANAEMIA | PH 1.60 PHARMACOECONOMICS | MI 1.3 EPIDEMEOLOGICAL BASIS OF INFECTIOUS DISEASES | MEDICOLEGAL AUTOPSY CLASS-INTRODUCTION | |||
DAY 2 | CLINICAL POSTING | SU 2.2 Clinical Features of shock & it’s appropriate treatment | PA 7.3 CARCINOGENESIS (SGD) | MI 1.4 METHODS OF STERILISATION AND DISINFECTION(SGD) | MI 1.2 GRAM STAIN - DOAP | ||||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.63 DRUG REGULATIONS | PA 7.2 MOLECULAR BASIS OF CANCER(SGD) | DOAP PRACTICALS - CHRONIC INFLAMMATION | ||||
DAY 4 | CLINICAL POSTING | 2.4 CM - PLANNING, IMPLEMENTING AND EVALUATING VACCINATION PROGRAMME FOR COVID 19 PANDEMIC (SGD) | MI 1.5 EQUIPMENTS IN STERILISATION AND DISINFECTION | PA 7.2 MOLECULAR BASIS OF CANCER (SGD) | PH 1.7 MANAGEMENT OF ADR | ||||
DAY 5 | CLINICAL POSTING | 2.3 Serological tests and their performance parameters I(SGD) | PA 7.2 MOLECULAR BASIS OF CANCER (SGD) | SGD PH.1.10 Describe Parts of a correct ,complete and legilible prescription. Identify errors in prescription and correct appropriately. | SGD PH.1.10 Describe Parts of a correct ,complete and legilible prescription. Identify errors in prescription and correct appropriately. | ||||
DAY 6 | CLINICAL POSTING | IA 1 PATH - 1 | AETCOM MODULE 2.5 IDENTY, DISCUSS AND DEFINED MEDICO - LEGAL, SOCIO - LEGAL, SOCIO - CULTURAL AND ETHICAL ISSUES AS IT PERTAINS TO PATIENT AUTONOMY, PATIENT RIGHTS AND SHARED RESPONSIBILITY IN HEALTH CARE | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | 1.64 PHASES OF CLINICAL TRIALS, NEW DRUG DEVELOPMENT | MI 1.5 APPROPRIATE METHOD OF STERILISATION AND DISINFECTION IN SPECIAL SITUATIONS(SGD) | FM 1.1 MEDICAL JURISPRUDENCE | INTEGRATED WITH MEDICINE | ||||
DAY 2 | CLINICAL POSTING | Su 3.1 Blood products & Complications of blood transfusion | PA 11.1 COMMON CYTOGENETIC MUTATIONS IN CHILDHOOD (SGD) | MI 1.7 STRUCTURE AND FUNCTION OF IMMUNE SYSTEM | MI 1.2 GRAM STAIN-DOAP | ||||
DAY 3 | CLINICAL POSTING | CM8.1 Epidemiology of Smallpox/Chicken pox | PH 1.64 GOOD CLINICAL PRACTICE | PA 11.1 COMMON CYTOGENETIC MUTATIONS IN CHILDHOOD (SGD) | PRACTICALS MICRO 1.2 GRAM STAIN DOAP PATH 6.7 INFARCT | ||||
DAY 4 | CLINICAL POSTING | CM8.1 Epidemiology of Measles,Mumps and Rubella | MI 1.7 ANTIGEN | PA 7.4 EFFECTS OF TUMOUR ON HOST (SGD), HOST DEFENCE AGAINST TUMOURS, LAB DIAGNOSIS OF CANCER | SDL - PH 1.8 MANAGEMENT OF DRUG INTERACTIONS | ||||
DAY 5 | CLINICAL POSTING | 2.3 Serological tests and their performance parameters I(SGD) | PA 7.4 EFFECTS OF TUMOUR ON HOST (SGD), HOST DEFENCE AGAINST TUMOURS, LAB DIAGNOSIS OF CANCER | SDL - BIO ASSAY AND BIOSTANDARDISATION | DOAP - PH 4.1 ADMINISTER DRUGS THROUGH VARIOUS ROUTES IN A SIMULATED ENVIRONMENT USING MANNEQUINES | ||||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 4.1 PYREXIA OF UNKNOWN ORIGIN | PH 1.6 PHARMACOVIGILANCE & ADR REPORTING SYSTEMS | MI 1.10 COMMONLY USED SEROLOGICAL DIAGNOSTIC METHODS | F.M 1.2 HISTORY OF FORENSIC MEDICINE | ||||
DAY 2 | CLINICAL POSTING | Su 4.2 Clinical Features of burns & appropriate management | PA 9.1 PRINCIPLES AND MECHANISMS OF IMMUNITY | MI 1.7 ANTIBODY | MI 1.2 GRAM STAIN - DOAP | ||||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.14 ANS, CHOLINERGICS (SGD) | P 9.2 HYPERSENSITIVITY DISORDERS (SGD) | DOAP PATH 6.7 INFARCT | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Influenza&SARS | MI 1.10 COMMONLY USED SEROLOGICAL DIAGNOSTIC METHODS(SGD) | P 9.2 HYPERSENSITIVITY DISORDERS (SGD) | PH 1.14 ANS, ANTICHOLINERGICS (SGD) | ||||
DAY 5 | CLINICAL POSTING | 2.2 Emerging and Re emerging infections - early diagnosis I (SGD) | PA 9.3 HLA, TRANSPLANT REJECTION (SGD) | SGD PH 3.4 To Recognize and report an adverse drug reaction | SGD PH 3.4 To Recognize and report an adverse drug reaction | ||||
DAY 6 | CLINICAL POSTING | IA - GENERAL Pharmacology | AETCOM - 2.4 1. DEMONSTRATE ABILITY TO WORK IN A TEAM OF PEERS AND SUPERIORS | SPORTS AND EXTRA CURRICULAR ACTIVITY | |||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 5.18 JAUNDICE | PH 1.14 ANS, ANTICHOLINERGICS (SGD) | MI 1.7 COMPLEMENT | FM 1.3 LEGAL PROCEDURE | ||||
DAY 2 | CLINICAL POSTING | S U 5.1 Wound Healing & factors affecting wound healing | PA 9.4 AUTOIMMUNITY (SGD) | MI 1.10 AUTOIMMUNITY | MI 1.2 GRAM STAIN - DOAP | INTEGRATION WITH PATHOLOGY | |||
DAY 3 | CLINICAL POSTING | CM8.1Epidemiology of Swine Flu&Avian Flu | PH 1.13 ADRENERGICS (SGD) | PA 9.5 AUTOIMMUNE DISORDERS SLE (SGD) | DOAP PATH 3.2 AMYLOIDOSIS IN SPECIMEN | ||||
DAY 4 | CLINICAL POSTING | CM8.1 Epidemiology of Tuberculosis - 1 | MI 1.9 IMMUNOLOGICAL BASIS OF VACCINE AND UIP(SGD) | PH 1.13 ANTIADRENERGICS (SGD) | |||||
DAY 5 | CLINICAL POSTING | 2.2 Emerging and Re emerging infections - early diagnosis II(SGD) | PA PRIMARY IMMUNODEFICIENCY DISORDERS | SGD PH 1.12 PEDIATRIC AND GERIATRIC DOSAGE CALCULATION | SGD PH 1.12 PEDIATRIC AND GERIATRIC DOSAGE CALCULATION | ||||
DAY 6 | CLINICAL POSTING | IA I - Microbiology / AETCOM MODULE 2.2: describe and discuss the role of autonomy and shared resonsibility as a guiding principle in patient care | |||||||
DAY 7 | |||||||||
THIRD MONTH | DAY 1 | CLINICAL POSTING | IM 18.1 STROKE | PH 1.13 ANTIADRENERGICS (SGD) | MI 1.8 IMMUNE RESPONSE | FM 1.3 CRIMINAL PROCEDURE CODE | |||
DAY 2 | CLINICAL POSTING | SU 5.3 Types of Wound & management of wounds | PA 9.6 HIV AND AIDS (INTEGRATION) | MI 2.7 AIDS | MI 1.2 GRAM STAIN - DOAP | INTEGRATION WITH MICRO | |||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | SGD PH 1.58 DRUGS USED IN OCULAR DISORDERS | PA 9.7 OTHER AUTOIMMUNE DISORDERS | DOAP PATH 8.3 CYTOLOGYSTAINING | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Acute Respiratory Infections | MI 1.10 ANTIGEN ANTIBODY REACTION (SGD) | PA CONGENITAL HEART DISEASE | PH 1.17 LOCAL ANASTHETICS | ||||
DAY 5 | CLINICAL POSTING | 2.2 Emerging and Re emerging infections - early diagnosis III(SGD) | PA 7.5 IMMUNE RESPONSE TO CANCER (SDL) | SGD PH 3.2 PERFORM AND INTERPRET A CRITICAL APPRAISAL(AUDIT) OF A GIVEN PRESCRIPTION | SGD PH 3.2 PERFORM AND INTERPRET A CRITICAL APPRAISAL(AUDIT) OF A GIVEN PRESCRIPTION | ||||
DAY 6 | CLINICAL POSTING | IA - PATH - 2 | AETCOM MODULE 2.5 IDENTY, DISCUSS AND DEFINED MEDICO - LEGAL, SOCIO - LEGAL, SOCIO - CULTURAL AND ETHICAL ISSUES AS IT PERTAINS TO PATIENT AUTONOMY, PATIENT RIGHTS AND SHARED RESPONSIBILITY IN HEALTH CARE | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 18.17 CVA | PH 1.15 SKELETAL MUSCLE RELAXANTS | MI 1.9 INFECTION AND IMMUNITY(SDL) | FM 1.3 INDIAN PENAL CODE,INDIAN EVIDENCE ACT | ||||
DAY 2 | CLINICAL POSTING | PA - TB LUNG (SGD) | PA - TB LUNG (SGD) | MI 1.11 IMMUNOLOGY OF TRANSPLANTATION(SGD) | MI1.2 GRAM STAIN -DOAP | ||||
DAY 3 | CLINICAL POSTING | CM8.1Epidemiology of Typhoid | PH 1.16 NSAIDS | PA 10.2 CYSTICERCOSISPA 10.4 COMMON BACTERIAL, VIRAL, PROTOZOAL INFECTIONS (SDL) | DOAP PATH 8.3 CYTOLOGYSTAINING, TB | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Food Poisoning | MI 1.11 IMMUNOLOGY OF TRANSPLANTATION(SGD) | PA 10.4 COMMON BACTERIAL, VIRAL, PROTOZOAL INFECTIONS (SDL) | PH 1.16 NSAIDS | ||||
DAY 5 | CLINICAL POSTING | Social obstetrics | PA 11.1 COMMON CYTOGENETIC MUTATIONS IN CHILDHOOD (SGD) | SDL : - DRUGS AFFECTING PEPTIDE DERIVED AUTACOIDS | SGD - PH 1.16 5 HT MODULATING DRUGS & DRUGS FOR MIGRAINE | ||||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.16 PROSTAGLANDINS, LEUKOTRIENES AND PLATELET ACTIVATING FACTOR | MI 1.11 TUMOUR IMMUNITY | FM 1.3 CIVIL & CRIMINAL CASES | INTEGRATED WITH MEDICINE | ||||
DAY 2 | CLINICAL POSTING | PA 10.1 PATHOGENESIS AND PATHOLOGY OF MALARIA PA 10.3 LEPROSY | PA 27.4, 27.6 RHEUMATIC FEVER, INFECTIVE ENDOCARDITIS | MI 2.1 RHEUMATIC FEVER AND DIAGNOSIS | MI 1.2 GRAM STAIN-DOAP | INTEGRATION WITH PATHOLOGY | |||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.24 DIURETICS | PA 11.1 COMMON CYTOGENETIC MUTATIONS IN CHILDHOOD (SGD) | PRACTICALS MICRO 1.2 GRAM STAIN DOAP PATH 27.8 ABNORMALITIES IN CFT IN ACUTE CORONARY SYNDROME | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Soil borne Helminths | MI 1.10 IMMUNODEF DISORDERS | PA 11.3 STORAGE DISORDERS OF CHILDHOOD (SDL) | SDL - G87PH 1.24ANTI-DIURETICS | ||||
DAY 5 | CLINICAL POSTING | Anatomy of the uterus | PA 11.3 STORAGE DISORDERS OF CHILDHOOD (SDL) | DOAP - PH 4.1 ADMINISTER DRUGS THROUGH VARIOUS ROUTES IN A SIMULATED ENVIRONMENT USING MANNEQUINES | DOAP - PH 4.1 ADMINISTER DRUGS THROUGH VARIOUS ROUTES IN A SIMULATED ENVIRONMENT USING MANNEQUINES | ||||
DAY 6 | CLINICAL POSTING | IA - ANS | AETCOM - 2.4 1. DEMONSTRATE ABILITY TO WORK IN A TEAM OF PEERS AND SUPERIORS | SPORTS AND EXTRA CURRICULAR ACTIVITY | |||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 17.1 HEADACHE | PH 1.25 ANTIPLATELETS | MI 2.2 INFECTIVE ENDOCARDITIS(SGD) | FM 1.3 POLICE INQUEST & MAGISTRATE INQUEST | ||||
DAY 2 | CLINICAL POSTING | Su 6.1 Aetiology and pathogenesis of surgical infection | PA 12.1 AIR POLLUTION (SDL) | MI 7.1 PATHOGENESIS &LAB DIAG OF INF IN GENITOURINARY SYSTEM(SGD) | MI 1.2 AFB DOAP | ||||
DAY 3 | CLINICAL POSTING | CM8.1 Epidemiology of Viral Hepatitis | PH 1.25 ANTICOAGULANTS | PA 12.1 TOBACCO, ALCOHOL DISORDERS (SDL) | DOAP PATH PA 13.5, 14.3 PERIPHERAL SMEAR | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Acute Diarrhoeal Disease | MI 1.10 Hypersensitivity | PA OBESITY | SGD - PH 1.25 FIBRINOLYTICS AND PLASMA EXPANDERS | ||||
DAY 5 | CLINICAL POSTING | Anatomy of the ovaries | PA 27.1 ATHEROSCLEROSIS (SGD) | SGD PH 1.28 DRUGS FOR ISCHEMIC HEART DESEASE & MI | SGD PH 1.28 DRUGS FOR ISCHEMIC HEART DESEASE & MI | INTEGRATED WITH PATH AND MEDICINE | |||
DAY 6 | CLINICAL POSTING | AET COM - Micro: Module 2.2 : Describe and discuss the role of non-maleficence as a guiding principle in patient care | |||||||
DAY 7 | |||||||||
FOURTH MONTH | DAY 1 | CLINICAL POSTING | PH1.29 DRUGS USED IN CONGESTIVE HEART FAILURE | PH1.29 DRUGS USED IN CONGESTIVE HEART FAILURE | MI 7.3 CULTURE IDENTIFICATION OF E.COLI, KLEBSIELLA, PROTEUS(SGD) | AUTOPSY CLASS-INTRODUCTION,INCISION,PROCEDURE | INTEGRATED WITH MEDICINE | ||
DAY 2 | CLINICAL POSTING | S U 7.1 Surgical Audit | PA 27.3 HEART FAILURE, VALVULAR HEART DISEASE | MI 7.2 SEXUALLY TRANSMITTED INFECTIONS(SGD) | MI 1.2 AFB - DOAP | ||||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.31 DRUGS FOR DYSLIPIDEMIA (SDL) | PA 11.2 TUMOUR AND TUMOUR LIKE LESIONS OF CHILDHOOD (SGD) | DOAP PATH PA 13.5, 14.3 PERIPHERAL SMEAR | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Plague | MI 2.5 Systemic Mycoses | PA 27.9 CARDIOMYOPATHIES, ARRYTHMIAS (SGD) | PH 1.30 ANTIARRHYTHMIC DRUGS | INTEGARTED PATH | |||
DAY 5 | CLINICAL POSTING | Anatomy of Fallopian tubes | PA 27.7, 27.10 PERICARDITIS, PERICARDIAL EFFUSION, SYPHILIS IN CVS, CARCINOID, PROSTHETIC VALVES (SDL) | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT AUTOCOIDS | SGD PH 3.5 TO PREPARE AND EXPLAIN A LIST OF P-DRUGS FOR A GIVEN CASE/CONDITION | ||||
DAY 6 | CLINICAL POSTING | IA - PATH - 3 | AETCOM MODULE 2.5 IDENTY, DISCUSS AND DEFINED MEDICO - LEGAL, SOCIO - LEGAL, SOCIO - CULTURAL AND ETHICAL ISSUES AS IT PERTAINS TO PATIENT AUTONOMY, PATIENT RIGHTS AND SHARED RESPONSIBILITY IN HEALTH CARE | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.27 DRUGS FOR SHOCK | SDL - PH 1.28 DRUGS USED IN PERIPHERAL VASCULAR DISEASE | MI 2.5 Filaria | FM 1.4 COURTS IN INDIA | INTEGRATED WITH MEDICINE | |||
DAY 2 | CLINICAL POSTING | Su 14.1 Aseptic techniques sterilization and disinfection | PA HYPERTENSION, HYPERTENSIVE HEART DISEASE | MI 2.5 KALA AZAR(SGD) | MI 1.2 AFB - DOAP | ||||
DAY 3 | CLINICAL POSTING | CM8.1Epidemiology of Rabies | PH 1.26 DRUGS MODULATING RENIN ANGIOTENSIN AND ALDOSTERONE SYSTEM | PA VASCULITIS | DOAP PATH PA 16.6 PERIPHERAL SMEAR HEMOLYTIC ANEMIA | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Yellow Fever /Kayanur fever disease | MI 2.5 Common Parasites prevalent in India | PA BLOOD VESSEL TUMOURS | PH 1.27 ANTIHYPERTENSIVES | ||||
DAY 5 | CLINICAL POSTING | Pelvic floor Anatomy and supports of uterus | PA 13.1, 13.3, 13.4 HEMATOPOIESIS, ANAEMIA (SGD) | PH 1.35 DRUGS USED IN ANEMIAS AND COLONY STIMULATING FACTORS | PH 1.35 DRUGS USED IN ANEMIAS AND COLONY STIMULATING FACTORS | INTEGRATED PATH AND PHYSIOLOGY | |||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.27 ANTIHYPERTENSIVES | PH 1.27 ANTIHYPERTENSIVES | MI 2.5 PERIPHERAL SMEAR EXAMINATION-MALARIA, FILARIA(SGD) | FM 1.4 JUVENILE JUSTICE BOARD,MAGISTRATE COURT | INTEGRATED MEDICINE | |||
DAY 2 | CLINICAL POSTING | PA 14.1, 14.2 MICROCYTIC ANEMIA (SGD) | PA 14.1, 14.2 MICROCYTIC ANEMIA (SGD) | MI 2.4 AGENTS CAUSING ANEMIA | MI 1.2 AFB - DOAP | INTEGRATED WITH PATHOLOGY | |||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.19 ANTIDEPRESSANTS & ANXIOLYTICS | PA 15.1, 15.2 MACROCYTIC ANEMIA (SGD) | DOAP PATH PA 15.3 PERIPHERAL SMEAR MACROCYTIC ANEMIA | ||||
DAY 4 | CLINICAL POSTING | CM8.1 Epidemiology of Salmonellosis/Brucellosis | MI 4.1 ANAEROBIC INFECTIONS | PA 15.4 NON MEGALOBLASTIC MACROCYTIC ANEMIA (SDL) | PH 1.19 ANTIDEPRESSANTS & ANXIOLYTICS | ||||
DAY 5 | CLINICAL POSTING | MI 4.3 CULTURE IDENTIFICATION OF STAPHYLOCOCCUS AUREUS(SGD) | PA 16.1, 16.2, 16.5 HEMOLYTIC ANEMIA- DEFN, CLSSIFICATION, PATHO, C.F, INDICES, P.S | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT CVS | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT CVS | ||||
DAY 6 | CLINICAL POSTING | IA Pharmacology - CVS & Diuretics | AETCOM - 2.4 1. DEMONSTRATE RESPECT IN RELATIONSHIP WITH PATIENTS, FELLOW TEAM MEMBERS, SUPERIORS AND OTHER HEALTH CARE WORKERS | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PA 16.1, 16.2, 16.5 HEMOLYTIC ANEMIA- DEFN, CLSSIFICATION, PATHO, C.F, INDICES, P.S | PH 1.18 GENERAL ANAESTHETICS & PAM | MI3.1 GASTROINTESTINAL INFECTIVE SYNDROMES - LAB DIAGNOSIS | FM 1.5 COURT PROCEDURES-SUMMONS,CONDUCT MONEY | INTEGRATED WITH MEDICINE | |||
DAY 2 | CLINICAL POSTING | Su16.1 Minimal invasive surgery – advantage and disadvantage | PA 16.3 THALLASEMIA (SGD) | MI 4.3 SKIN AND SOFT TISSUE INFECTIONS- BACTERIA | MI 1.2 AFB - DOAP | ||||
DAY 3 | CLINICAL POSTING | CM8.1Epidemiology of Rickettsial disease -1 | PH 1.18 GENERAL ANAESTHETICS & PAM | PA 16.3 SICKLE CELL ANEMIA (SGD) | DOAP PATH PA 16.6 PERIPHERAL SMEAR HEMOLYTIC ANEMIA | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Leishmaniasis / Hydatid disease | MI 8.2 OPPORTUNISTIC INFECTIONS(SGD) | PA 18.2 ACUTE LEUKEMIA (SGD) | PH 1.19 SEDATIVES & HYPNOTICS | ||||
DAY 5 | CLINICAL POSTING | Physiology of Ovulation | PA 18.2 ACUTE LEUKEMIA (SGD) | SGD PH 3.6 DEMONSTRATE HOW TO OPTIMIZE INTERACTION WITH PHARMACEUTICAL REPRESENTATIVE TO GET AUTHENTIC INFORMATION ON DRUGS | SGD PH 3.3 PERFORM A CRITICAL EVALUATION OF THE DRUG PROMOTIONAL LITERATURE | ||||
DAY 6 | CLINICAL POSTING | AET COM - Micro: Module 2.2 : Describe and discuss the role of non-maleficence as a guiding principle in patient care | |||||||
DAY 7 | |||||||||
FIFTH MONTH | DAY 1 | CLINICAL POSTING | PH 1.19 ANTI -EPILEPTICS | PH 1.19 ANTI -EPILEPTICS | MI 4.3 SKIN AND SOFT TISSUE INFECTIONS- VIRAL | FM 1.5 COURT PROCEDURES-TYPES OF WITNESSES,RECORDING OF OATH | INTEGRATED MEDICNE | ||
DAY 2 | CLINICAL POSTING | PA 18.2 ACUTE LEUKEMIA (SGD) | PA 21.2, 21.3 PLATELET DISORDERS DIFF PLT & CLOTTING DISORDERS (SGD) | MI 4.3 CULTURE IDENTIFICATION OF PSEUDOMONAS(SGD) | MI 1.2 AFB - DOAP | ||||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.19 OPIODS AGONISTS AND ANTAGONISTS | PA 21.2, 21.3 PLATELET DISORDERS DIFF PLT & CLOTTING DISORDERS (SGD) | DOAP PATH PA 19.7 SPLENOMEGALY | ||||
DAY 4 | CLINICAL POSTING | CM8.1Epidemiology of Rickettsial diseases -2 | MI 4.3 SKIN AND SOFT TISSUE INFECTIONS- PARASITIC(SDL) | PA 16.4 ACQUIRED HEMOLYTIC ANEMIAS | PH 1.19 OPIODS AGONISTS AND ANTAGONISTS | ||||
DAY 5 | CLINICAL POSTING | Physiology of Menstruation | PA 21.2 VASCULAR DISORDERS (SGD) | SGD PH 2.2 OSPE-ORAL REHYDRATION SOLUTION PREPARATION | SGD PH 3.8 COMMUNICATE EFFECTIVELY WITH A PATIENT ON THE PROPER USE OF PRESCRIBED MEDICATION | ||||
DAY 6 | CLINICAL POSTING | AETCOM MODULE 2.7 IDENTIFY DISCUSS AND DEFINED, MEDIO LEGAL, SOCIO CULTURAL AND ETHICAL ISSUES AS THEY PERTAIN TO CONSENT FOR SURGICAL PROCEDURES | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.19 DRUGS FOR PARKINSONISM | SGD PH 1.19 DRUGS FOR NEURO DEGENERATIVE DISORDERS | MI 8.6 ANTIBIOGRAM | AUTOPSY CLASS-MAGISTRATE INQUIRY | ||||
DAY 2 | CLINICAL POSTING | PA 18.2 CHRONIC LEUKEMIAS (SGD) | PA 18.2 CHRONIC LEUKEMIAS (SGD) | MI 3.1 CULTURE IDENTIFICATION OF SALMONELLA TYPHI AND PARATYPHI B | MI 1.2 AFB - DOAP | ||||
DAY 3 | CLINICAL POSTING | CM8.1Epidemiology of Leprosy | SGD PH 1.20 EFFECTS OF ACUTE AND CHRONIC ALCOHOL INTAKE | PA MPD, THYMUS | DOAP PATH PA 20.1 PLASMA CELLMYELOMA | ||||
DAY 4 | CLINICAL POSTING | CM8.1 Epidemiology of Tetanus | MI 3.1 MICROBIAL AGENTS CAUSING DIARRHOEA | PA 19.1, 19.3 CAUSES AND DIFF FEATURES OF LYMPHADENOPATHY (SGD), TB LN | PH 1.21 SYMPTOMS AND MANAGEMENT OF METHANOL AND ETHANOL POISONING | ||||
DAY 5 | CLINICAL POSTING | MI 3.1 MICROBIAL AGENTS CAUSING DIARRHOEA (SGD) | PA 19.4 HODGKIN LYMPHOMA (SGD) | SGD PH 1.23 PROCESS AND MECHANISM OF DEADDICTION | SGD PH 5.1 COMMUNICATE WITH THE PATIENT WITH EMPATHY AND ETHICS ON ALL ASPECTS OF DRUG USE | ||||
DAY 6 | CLINICAL POSTING | SDL -FORENSIC MEDICINE-MEDICOLEGAL CERTIFCATION OF DEATH | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.19 ANTI -PSYCHOTICS & ANTI MANIAC DRUGS | PH 1.19 ANTI -PSYCHOTICS & ANTI MANIAC DRUGS | MI 3.1 MICROBIAL AGENTS CAUSING DIARRHOEA (SGD) | FM 1.5 COURT PROCEDURES-COURT QUESTIONS,RECORDNG OFEVIDENCE,CONDUCT OF DOCTOR IN WITNESS BOX | INTEGRATED MEDICNE | |||
DAY 2 | CLINICAL POSTING | Su 17.4 pathophisiology and mechanism of head injuries. | PA 19.4 NON HODGKIN LYMPHOMA | MI 3.1 MICROBIAL AGENTS CAUSING DIARRHOEA - CHART DISCUSSION OF PARASITIC CYSTS AND OVA | MI 1.2 AFB-DOAP | ||||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.19 ANTI -PSYCHOTICS & ANTI MANIAC DRUGS | PA 19.4 NON HODGKIN LYMPHOMA | DOAP PATH PA 19.5 HODGKIN LYMPHOMA | ||||
DAY 4 | CLINICAL POSTING | CM8.1 Epidemiology of AIDS | MI 3.2 MICROBIAL AGENTS CAUSING DYSENTRY(SGD) | PA ATELACTASIS, ACUTE LUNG INJURY | SDL - PH 1.33 DRUGS FOR COUGH (ANTI-TUSSIVES, EXPECTORANTS) | ||||
DAY 5 | CLINICAL POSTING | Anatomy of Fallopian tubes | PA 26.3 BRONCHIECTASIS, ASTHMA (SGD) | SGD - PH 1.32 DRUGS FOR BRONCHIAL ASTHMA & COPD | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT RS | INTEGRATED WITH PHARMACOLOGY | |||
DAY 6 | CLINICAL POSTING | IA Pharmacology - CNS | AETCOM - 2.4 1. DEMONSTRATE RESPECT IN RELATIONSHIP WITH PATIENTS, FELLOW TEAM MEMBERS, SUPERIORS AND OTHER HEALTH CARE WORKERS | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH1.37 INTRODUCTION TO HORMONES AND ANTERIOR PITUITARY HORMONES | PH1.37 INTRODUCTION TO HORMONES AND ANTERIOR PITUITARY HORMONES | MI 3.1 MICROBIAL AGENTS CAUSING DIARRHOEA - CHART DISCUSSION OF PARASITIC CYSTS AND OVA(SGD) | FM 1.6 COURT PROCEDURES-OFFENCES PERJURY | ||||
DAY 2 | CLINICAL POSTING | SU 17.5 neurological assessment & GCS in head injury | PA 26.1 PNEUMONIA (INTEGRATION) | MI 6.1 ETIOPATHOGENESIS, LAB DIAG AND PREVENTION OF INFECTION OF UPPER AND LOWER RESPIRATORY TRACT- BACTERIAL | MI 1.2 AFB - DOAP | INTEGRATED WITH MICRO | |||
DAY 3 | CLINICAL POSTING | CM14.1 Hospital waste management | PH1.37 SEX HORMONES AND THEIR ANALOGUES - ANDROGENS / ANABOLIC STEROIDS | PA 26.3 COPD (SGD) | DOAP PATH 21.3 DIFF PLT FROM CLOTTING DISORDERS BASED ON CLINICAL AND HEMAT FEATURES | ||||
DAY 4 | CLINICAL POSTING | CM 14.2 Various methods of treatment of hospital waste | MI 6.1 ETIOPATHOGENESIS, LAB DIAG AND PREVENTION OF INFECTION OF UPPER AND LOWER RESPIRATORY TRACT- BACTERIAL | PA 26.5 OCCUPATIONAL LUNG DISEASES (SGD) | PH1.37 SEX HORMONES AND THEIR ANALOGUES - ESTROGEN / PROGESTERONES | ||||
DAY 5 | CLINICAL POSTING | PH 1.39 DRUGS USED IN CONTRACEPTION | PA DISEASES OF VASCULAR ORIGIN OF LUNG, LUNG TRANSPLANTATION | PH 1.39 DRUGS USED IN CONTRACEPTION | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT HORMONES | INTEGRATED OG | |||
DAY 6 | CLINICAL POSTING | IA II - Microbiology / AETCOM module 2.2 describe and discuss the role of benefiscence of a guiding principle in patient care | |||||||
DAY 7 | |||||||||
SIXTH MONTH | DAY 1 | CLINICAL POSTING | PH 1.36 DRUGS FOR DIABETES MELLITUS | PH 1.36 DRUGS FOR DIABETES MELLITUS | MI 3.3 ENTERIC FEVER(SGD) | FM 1.7 DYING DECLARATION & DYING DEPOSITION | INTEGRATED MEDICINE | ||
DAY 2 | CLINICAL POSTING | PA 26.6 TUMOURS OF LUNG (INTEGRATION) | PA 26.6 TUMOURS OF LUNG (INTEGRATION) | MI 3.4 DIAGNOSIS OF ENTERIC FEVER | MI 1.2 AFB-DOAP | INTEGRATED WITH MEDICINE | |||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.36 DRUGS FOR THYROID DISORDERS | PA 26.7 MESOTHELIOMA, PLEURAL DISEASES (SDL) | DOAP PATH 8.3 CYTOLOGYSTAINING | ||||
DAY 4 | CLINICAL POSTING | CM14.2 Hospital visit related to Hospital waste management | MI 3.5 CAUSATIVE AGENTS OF FOOD POISONING(SGD) | PA NON NEO LESIONS OF ORAL CAVITY, UPPER AIRWAYS, SALIVARY GLAND TUMORS, CONGENITAL ANAMOLIES OF GIT, ESOPHAGUS | PH 1.36 DRUGS FOR OSTEOPOROSIS | ||||
DAY 5 | CLINICAL POSTING | PH 1.41 UTERINE RELAXANTS AND STIMULANTS | PA 24.1 ORAL CANCERS (SDL) | SGD - PH 1.41 UTERINE RELAXANTS AND STIMULANTS | SGD PH 1.40 DRUGS USED IN THE TREATMENT OF INFERTILITY AND ERECTILE DYSFUNCTION | INTEGRATED OG | |||
DAY 6 | CLINICAL POSTING | IA - PATH - 4 | AETCOM MODULE 2.7 IDENTIFY DISCUSS AND DEFINED, MEDIO LEGAL, SOCIO CULTURAL AND ETHICAL ISSUES AS THEY PERTAIN TO CONSENT FOR SURGICAL PROCEDURES | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.38 CORTICOSTEROIDS | PH 1.38 CORTICOSTEROIDS | MI 3.5 CAUSATIVE AGENTS OF FOOD POISONING | FM 1.8 MEDICOLEGAL PRACTICE | INTEGRATED MEDICINE | |||
DAY 2 | CLINICAL POSTING | PA 24.4 CA STOMACH (INTEGRATION) | PA 24.4 CA STOMACH (INTEGRATION) | MI 5.1 MENINGITIS CHART DISCUSSION RABIES | 5.3 MICROBIAL AGENTS CAUSING MENINGITIS(SGD) | INTEGRATED WITH SURGERY | |||
DAY 3 | CLINICAL POSTING | CM8.2 Non communicable diseases-INTRODUCTION | SGD - F182PH 1.34 ACID PEPTIC DISEASE, GERD | PA 24.2 PEPTIC ULCER | DOAP PATH PA 24.3 PEPTIC ULCER | ||||
DAY 4 | CLINICAL POSTING | CM8.2 Non communicable diseases-Epidemiology and control of Diabetes | MI 5.1MENINGITIS(SGD) | PA MALABSORPTION AND DIARRHOEA | PH 1.34 PROKINETICS, ANTIEMETICS | ||||
DAY 5 | CLINICAL POSTING | Puberty and changes after puberty | PA 24.6 INFLAMMATORY BOWEL DISEASES (SGD), APPENDIX PERITONEUM | PH 1.34 DRUGS FOR INFLAMMATORY BOWEL DISEASE, IRRITABLE BOWEL DISORDERS | PH 1.34 DRUGS FOR INFLAMMATORY BOWEL DISEASE, IRRITABLE BOWEL DISORDERS | INTEGRATED WITH PATH , SURGERY | |||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | MI 5.1 MENINGITIS | SGD PH 1.34 ANTIDIARRHOEALS & LAXATIVES | MI 5.1 MENINGITIS(SGD) | FM 1.9 IMPORTANCE OF DOCUMENTATION IN MEDICAL PRACTICE IN REGARD TO MEDICOLEGAL EXAMINATION | INTEGRATION WITH MEDICINE | INTEGRATION WITH RADIODIANOSIS,MEDICINE | ||
DAY 2 | CLINICAL POSTING | PA 24.7 CA COLON, POLYPS OF INTESTINE AND STOMACH (INTEGRATION) | PA 24.7 CA COLON, POLYPS OF INTESTINE AND STOMACH (INTEGRATION) | MI 3.6 ACID PEPTIC DISEASE(SGD) | 6.3 LRTI AGENTS & URTI agents (SGD) | INTEGRATED WITH SURGERY | |||
DAY 3 | CLINICAL POSTING | PANDEMIC MODULE 2.5 - THERAPEUTIC STRATEGIES INCLUDING NEW DRUG DEVELOPMENT | PH 1.42 GENERAL PRINCIPLES OF CHEMOTHERAPY | PA 25. 1 JAUNDICE, BILIRUBIN METABOLISM | DOAP PATH PA 25.6 OBS VS NON OBS JAUNDICE | ||||
DAY 4 | CLINICAL POSTING | CM8.2 Epidemiology and control of cancers -1 | MI 5.2 MICROBIAL AGENTS CAUSING ENCEPHALITIS | PA25.2, 25.5- HEPATIC FAILURE, PORTAL HT (SGD) | PH 1.42 GENERAL PRINCIPLES OF CHEMOTHERAPY | ||||
DAY 5 | CLINICAL POSTING | Fertilisation and implantation | PA 25.3 TOXIC HEPATITIS (SGD) | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT CNS | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT CNS | ||||
DAY 6 | CLINICAL POSTING | IA Pharmacology - AUTOCOIDS, RS, GIT | AETCOM - 2.8 DEMONSTRATE EMPATHY IN PATIENT ENCOUNTERS | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 19.1 MOVEMENT DISORDERS | PH 1.43 ANTIBIOTIC STEWARDSHIP PROGRAM - BETA LACTAM ANTIBIOTICS | MI 6.1 ETIOPATHOGENESIS, LAB DIAG AND PREVENTION OF INFECTION OF UPPER AND LOWER RESPIRATORY TRACT- BACTERIAL | FM 1.9 IMPORTANCE OF DOCUMENTATION IN MEDICAL PRACTICE IN REGARD TO MEDICOLEGAL EXAMINATION CONT.. | INTEGRATED WITH MICRO | |||
DAY 2 | CLINICAL POSTING | 25.3 VIRAL HEPATITIS (INTEGRATION) | 25.3 VIRAL HEPATITIS (INTEGRATION) | MI 3.7 VIRAL HEPATITIS - ETIOLOGY AND LAB DIAGNOSIS | MI 6.2 URTI AGENTS(SGD) | INTEGRATED WITH MEDICINE , MICRO | |||
DAY 3 | CLINICAL POSTING | CM8.2Epidemiology and control of Stroke | PH 1.43 ANTIBIOTIC STEWARDSHIP PROGRAM - BETA LACTAM ANTIBIOTICS | PA 25.4 ALCOHOLIC LIVER DISEASE (SGD) | DOAP PATH PA 25.6 VIRAL HEPATITIS SEROLOGY PANEL | ||||
DAY 4 | CLINICAL POSTING | CM8.2 Epidemiology and control of cancers -2 | MI 6.1 ETIOPATHOGENESIS, LAB DIAG AND PREVENTION OF INFECTION OF UPPER AND LOWER RESPIRATORY TRACT- PARASITIC | PA INTRA HEPATIC BILIARY TRACT DISEASE | PH 1.43 ANTIBIOTIC STEWARDSHIP PROGRAM - SULPHONAMIDES | ||||
DAY 5 | CLINICAL POSTING | MI 6.2 URTI AGENTS(SGD) | PA BILIARY TRACT- GALL STONES, CHOLECYSTITIS, CA GALL BLADDER | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT GIT | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT GIT | ||||
DAY 6 | CLINICAL POSTING | IA III - Microbiology / AETCOM module 2: describe and discuss the role of a physician in healthcare system | |||||||
DAY 7 | |||||||||
SEVENTH MONTH | DAY 1 | CLINICAL POSTING | PH 1.43 ANTIBIOTIC STEWARDSHIP PROGRAM - FLUROQUINOLONES | MI 1.2 STOOL EXAMINATION (DOAP) | IA -LEGAL PROCEDURE & MEDICAL JURISPRUDENCE | INTEGRATED WITH MEDICINE | |||
DAY 2 | CLINICAL POSTING | PA 32.6 PANCREATIC CANCER,NEURO ENDOCRINE TUMOURS (INTEGRATION) | PA 32.6 PANCREATIC CANCER,NEURO ENDOCRINE TUMOURS (INTEGRATION) | MI 8.3 ONCOGENIC VIRUSES-RNA(SDL) | MI 6.2 URTI AGENTS (SGD) | INTEGRATED WITH SURGERY | |||
DAY 3 | CLINICAL POSTING | CM8.2 Epidemiology and control of RHD | PH 1.43 ANTIBIOTIC STEWARDSHIP PROGRAM - AMINOGLYCOSIDES | PA 28.1, 28.2 HISTOLOGY OF KIDNEY WITH INTRO TO RENAL FAILURE | DOAP PATH PA 23.3 TFT, RFT, LFT | ||||
DAY 4 | CLINICAL POSTING | CM8.2 Epidemiology and control of Blindness | MI 8.1 MICROBIAL AGENTS AND THEIR VECTORS CAUSING ZOONOTIC DISEASES | PA 28.5 GLOMERULONEPHRITIS (SGD) | PH 1.43 ANTIBIOTIC STEWARDSHIP PROGRAM - MACROLIDES AND MISCELLANEOUS ANTIBIOTICS | ||||
DAY 5 | CLINICAL POSTING | MI 6.1 ETIOPATHOGENESIS, LAB DIAG AND PREVENTION OF INFECTION OF UPPER AND LOWER RESPIRATORY TRACT- FUNGUS | PA 28.5 GLOMERULONEPHRITIS (SGD) | SGD PH 5.2 COMMUNICATE WITH THE PATIENT REGARDING OPTIMAL USE OF a)DRUG THERAPY, b)DEVICES AND c)STORAGE OF MEDICINES | SGD PH 5.2 COMMUNICATE WITH THE PATIENT REGARDING OPTIMAL USE OF a)DRUG THERAPY, b)DEVICES AND c)STORAGE OF MEDICINES | ||||
DAY 6 | CLINICAL POSTING | IA - PATH - 5 | PA 28.7 GLOMERULAR MANIFESTATIONS OF SYSTEMIC DISEASES | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.44 ANTITUBERCULAR DRUGS | PH 1.44 ANTITUBERCULAR DRUGS | MDR & XDR TUBERCULOSIS | FM 1.9 MEDICAL CERTIFICATION OF DEATH | INTEGRATED WITH PHARMACOLOGY, MEDICINE | |||
DAY 2 | CLINICAL POSTING | SU 22.1 Surgical Anatomy & physiology of thyroid | PA 28.5 GLOMERULONEPHRITIS (SGD) | MI 8.1 LAB DIAGNOSIS AND PREVENTION OF ZOONOTIC DISEASES (SGD) | 6.3 LRTI AGENTS(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM8.2 Epidemiology and control of Obesity | PH 1.45 DRUGS USED IN MDR AND XDR TB | PA 28.6 IG A NEPHROPATHY (SGD) | DOAP PATH PA 23.3 TFT, RFT, LFT | ||||
DAY 4 | CLINICAL POSTING | Cm8.2 Epidemiology and contol of Blindness | MI 4.3 SKIN AND SOFT TISSUE INFECTIONS- LEPROSY | PA 28.7 GLOMERULAR MANIFESTATIONS OF SYSTEMIC DISEASES | PH 1.46 ANTILEPROTIC DRUGS | INTEGRATED WITH PHARMACOLOGY | |||
DAY 5 | CLINICAL POSTING | Embrygenesis and development of the fetus | PA 28.9 ATN (SGD) | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT ANTIBIOTICS | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT ANTIBIOTICS | ||||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.55 ANTIMALARIAL DRUGS | PH 1.55 ANTIMALARIAL DRUGS | MI 8.2 OPPORTUNISTIC INFECTIONS(SGD) | FM 1.9 DOCUMENTS FOR ESTIMATION OF AGE BY PHYSICAL,DENTAL & RADIOLOGICAL EXAMINATION | INTEGRATED MEDICINE , MICRO, PATHOLOGY | |||
DAY 2 | CLINICAL POSTING | PA 28.8 DISEASES AFFECTING TUBULAR INTERISTITIUM (SGD) | PA 28.8 DISEASES AFFECTING TUBULAR INTERISTITIUM (SGD) | MI 7.3 URINARY TRACT INFECTIONS(SGD) | MI 2.6PERIPHERAL SMEAR - PLASMODIUM (DOAP) | INTEGRATED WITH PATHOLOGY | |||
DAY 3 | CLINICAL POSTING | CM8.2 Epidemiology and control of Accidents | PH 1.47 TREATMENT OF KALA AZAR | PA 28.10 ACUTE AND CHRONIC PYELONEPHRITIS (SGD) | PA 23.1 URINE EXAMINATION | ||||
DAY 4 | CLINICAL POSTING | CM8.2 Epidemiology and control of Injuries | MI 8.3 ONCOGENIC VIRUSES- DNA(SDL) | PA 28.11 VASCULAR DISEASES OF KIDNEY | PH 1.47 TREATMENT OF AMOEBIASIS | ||||
DAY 5 | CLINICAL POSTING | MI 8.4 EMERGING REEMERGING INFECTIONS | PA 28.12 CYSTIC DISEASES OF KIDNEY (SGD) | SGD PH 5.3 MOTIVATE PATIENTS WITH CHRONIC DISEASES TO ADHERE TO THE PRESCRIBED MANAGEMENT BY THE HEALTH CARE PROVIDER | SGD PH 5.3 MOTIVATE PATIENTS WITH CHRONIC DISEASES TO ADHERE TO THE PRESCRIBED MANAGEMENT BY THE HEALTH CARE PROVIDER | ||||
DAY 6 | CLINICAL POSTING | IA - Pharmacology - HORMONES | AETCOM - 2.8 DEMONSTRATE EMPATHY IN PATIENT ENCOUNTERS | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 19.9 MOVEMENT DISORDERS | PH 1.47 TREATMENT OF HELMINTHIC INFECTIONS | MI 2.5 KALA AZAR, MALARIA, AMEBIASIS, INTESTINAL HELMINTHS | FM 1.10 CAUSE OF DEATH IN PARTICULAR SCENARIO BY ICD 10 CODE | INTEGRATED WITH PHARMACOLOGY | |||
DAY 2 | CLINICAL POSTING | SU 22.2 Etiopathogenesis of thyroid swelling | PA 28.13 URINARY TRACT CALCULI & OBSTRUCTIVE UROPATHY (SGD) | MI 8.2 CULTURE IDENTIFICATION OF ASPERGILLUS SPECIES | MI 2.6 FILARIA(DOAP) | ||||
DAY 3 | CLINICAL POSTING | CM8.2 Epidemiology and control of Cardiovascular diseases | SGD - PH 1.47 TREATMENT OF HELMINTHIC INFECTIONS | PA 28.14 RENAL TUMOURS (SGD) | DOAP PATH PA 23.1 URINE EXAMINATION | ||||
DAY 4 | CLINICAL POSTING | CM8.2 Epidemiology and control of Oral diseases | MI 8.5 HEALTH CARE ASSOCIATED INFECTIONS(SGD) | PA URETER, BLADDER, URETHRA | PH 1.48 ANTIVIRAL DRUGS - INTRODUCTION AND DRUGS FOR HEPATITIS | ||||
DAY 5 | CLINICAL POSTING | PH 1.48 DRUGS FOR UTI AND STD | PA 28.16 UROTHELIAL TUMOURS | PH 1.48 DRUGS FOR UTI AND STD | SGD PH 5.4 EXPLAIN TO THE PATIENT THE RELATIONSHIP BETWEEN COST OF TREATMENT AND PATIENT COMPLIANCE | INTEGRATED OG | |||
DAY 6 | CLINICAL POSTING | IA IV Microbiology / AETCOM module 2.2: describe and discuss the role of justice as a guiding principle in patient care | |||||||
DAY 7 | |||||||||
EIGHT MONTH | DAY 1 | CLINICAL POSTING | IM 15.1 GI BLEEDING | PH 1.48 ANTI INFLUENZA DRUGS | MI ETIOPATHOGENESIS, LAB DIAG AND PREVENTION OF INFECTION OF UPPER AND LOWER RESPIRATORY TRACT- VIRAL | FM 1.10 CASE SCENARIO DISCUSSION | INTEGRATED WITH PHARMACOLOGY | ||
DAY 2 | CLINICAL POSTING | SU 22.3 clinical examination of thyroid & differential diagnosis | PA 8.1 DIAGNOSTIC ROLE OF CYTOLOGY AND ITS APPLICATION IN CLINICAL CARE (SGD) | MI 8.5 SURGICAL SITE NFECTIONS | MI - Rapid Diagnostic Tests (DOAP) | ||||
DAY 3 | CLINICAL POSTING | CM8.2 Epidemiology and control of Coronary artery disease | PH 1.48 ANTIVIRAL DRUGS - INTRODUCTION | PA 29.1 TESTICULAR TUMOURS (SGD) | DOAP PATH 8.3 CYTOLOGYSTAINING | ||||
DAY 4 | CLINICAL POSTING | CM8.3 NPCDCS-1 | MI 8.6 INFECTION CONTROL(SGD) | PA 29.1 TESTICULAR TUMOURS (SGD) | PH 1.48 DRUGS FOR HEPATITIS | ||||
DAY 5 | CLINICAL POSTING | Anatomy and development of the placenta | PA 29.3 BPH (SDL) | PH 1.48 DRUGS FOR HIV | PH 1.48 DRUGS FOR HIV | INTEGRATION MICRO MEDICINE | |||
DAY 6 | CLINICAL POSTING | IA - PATH - 6 | PA 8.1 DIAGNOSTIC ROLE OF CYTOLOGY AND ITS APPLICATION IN CLINICAL CARE | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.49 ANTI CANCER DRUGS | PH 1.49 ANTI CANCER DRUGS | MI 8.7 PERSONAL PROTECTIVE EQUIPMENTS - DONNING DOFFING TECHNIQUE | FM 1.11 CAUSE OF DEATH CERTIFICATE PER ICD 10 DOCUMENT | INTEGRATION MEDICINE | |||
DAY 2 | CLINICAL POSTING | PA 29.4, 29.5 CA PROSTATE, PROSTITIS (INTEGRATION) | PA 29.4, 29.5 CA PROSTATE, PROSTITIS (INTEGRATION) | MI 8.7 PERSONAL PROTECTIVE EQUIPMENTS(SGD) | MI8.15 Rapid Diagnostic Tests (DOAP) | INTEGRATED WITH SURGERY | |||
DAY 3 | CLINICAL POSTING | CM8.3 NPCDCS -2 | PH 1.49 ANTI CANCER DRUGS | PA 30.6 CERVICITIS AND PRECURSOR LESIONS(SGD) | DOAP PATH PA 23.3 SEMEN ANALYSIS | ||||
DAY 4 | CLINICAL POSTING | CM 8.2 Small group discussion on primodial prevention of NCDs | MI 8.6 INFECTION CONTROL(SGD) | PA 30.1 CA CERVIX (SGD) | PH 1.49 ANTI CANCER DRUGS | ||||
DAY 5 | CLINICAL POSTING | Maternal changes in pregnancy | PA 30.7, 30.8 ENDOMETRIOSIS, ADENOMYOSIS (SGD), VULVA, VAGINA, FALLOPIAN TUBE | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT ANTIVIRAL/ANTIPROTOZOAL DRUGS | SGD PH 3.1, 3.2 PRESCRIPTION WRITING / AUDIT ANTIVIRAL/ANTIPROTOZOAL DRUGS | ||||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 16.1 DIARRHOEAL DISORDER | PH 1.57 DRUGS USED IN SKIN DISORDERS (SDL) - ANTI FUNGAL | MI 4.3 SKIN AND SOFT TISSUE INFECTIONS-FUNGAL | AUTOPSY CLASS-SUDDEN DEATH | INTEGRATED WITH PHARMACOLOGY | |||
DAY 2 | CLINICAL POSTING | PA 30.9 ENDOMETRIAL HYPERPLASIA PA 30.2 CA ENDOMETRIUM (INTEGRATION) | PA 30.9 ENDOMETRIAL HYPERPLASIA PA 30.2 CA ENDOMETRIUM (INTEGRATION) | MI 8.8 BACTERIOLOGY OF WATER(SGD) | MI8.15 Rapid Diagnostic Tests (DOAP) | INTEGRATION WITH OG | |||
DAY 3 | CLINICAL POSTING | CM15.1 Mental health | PH 1.57 DRUGS USED IN SKIN DISORDERS (SDL) | PA 30.3 LEIOMYOMA, LEIOMYOSARCOMA(SGD) | DOAP PATH 8.3 CYTOLOGYSTAINING | ||||
DAY 4 | CLINICAL POSTING | CM15.2Mental health-Warning signs | MI 8.8 BACTERIOLOGY OF MILK(SDL) | PA 30.5 GTD (SGD) | SGD PH 1.22 DRUGS OF ABUSE (SGD) | ||||
DAY 5 | CLINICAL POSTING | PA 30.4 NEOPLASTIC LESIONS OF OVARY (INTEGRATION) | PA 30.4 NEOPLASTIC LESIONS OF OVARY (INTEGRATION) | SGD PH 5.5 LINE OF MANAGEMENT ON DRUG DEPENDENCE | SGD PH 5.6 DEMONSTRATE ABILITY TO EDUCATE PUBLIC AND PATIENTS ABOUT VARIOUS ASPECTS OF DRUG USE INCLUDING DRUG DEPENDENCE AND OVER THE COUNTER DRUGS | INTEGRATED WITH OG | |||
DAY 6 | CLINICAL POSTING | IA - Pharmacology - ANTIBACTERIAL, ANTIFUNGAL, ANTIHELMINTHIC DRUGS | AETCOM - 2.8 DEMONSTRATE EMPATHY IN PATIENT ENCOUNTERS | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.43 RATIONAL USE OF ANTIMICROBIALS | PH 1.43 RATIONAL USE OF ANTIMICROBIALS | MI 8.8 BACTERIOLOGY OF AIR (SDL) | FM 2.1 FORENSIC PATHOLOGY-TYPES OF DEATH | INTEGRATED MEDICINE | |||
DAY 2 | CLINICAL POSTING | PA 31.1, 31.4 BENIGN BREAST DISEASE, BREAST PA 31.2 CA BREAST (INTEGRATION) | PA 31.1, 31.4 BENIGN BREAST DISEASE, BREAST PA 31.2 CA BREAST (INTEGRATION) | MI 8.9 venepuncture technique(DOAP) | MI 1.2 GRAMS STAINREVISION(DOAP) | INTEGRATED WITH SURGERY | |||
DAY 3 | CLINICAL POSTING | CM15.3 National mental health program -Lecture | PH 1.59 ESSENTIAL MEDICINES | PA ENDOCRINE- PITUITARY | DOAP PATH PA 31.3 CA BREAST | ||||
DAY 4 | CLINICAL POSTING | CM15.3 National mental health program -Group discussion | MI 2.3 Blood Collection(DOAP) | PA 32.3 HYPOTHYROIDISM THYROIDITIS(SGD) | SGD - PH 1.59 HERBAL MEDICINES | ||||
DAY 5 | CLINICAL POSTING | Diagnosis of pregnancy | PA 32.2 THYROTOXICOSIS GRAVES, GOITRE (SGD) | SGD PH 5.7 LEGAL AND ETHICAL ASPECTS OF PRESCRIBING DRUGS | SGD PH 5.7 LEGAL AND ETHICAL ASPECTS OF PRESCRIBING DRUGS | ||||
DAY 6 | CLINICAL POSTING | IA V /AETCOM module 2.3 describe and discuss the role of justice as aguiding principle in patient care | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 6.1 HIV | SDL - PH 1.59 FIXED DOSE COMBINATIONS | MI 8.15 MOLECULAR DIAGNOSIS(SGD) | FM 2.1 FORENSIC PATHOLOGY-BRAIN DEATH,CORTICAL DEATH,BRAINSTEM DAETH | INTEGRATION WITH PATHOLOGY | |||
DAY 2 | CLINICAL POSTING | SU22.4 clinical features, classification & management of CA thyroid | PA 32.5 PARATHYROID (SGD) | MI 8.10SAMPLE COLLECTION(SGD) | MI1.2-AFB STAIN REVISION(DOAP) | ||||
DAY 3 | CLINICAL POSTING | CM15.3 National mental health program -Group discussion | SDL - PH 1.59 OVER THE COUNTER DRUGS | PA 32.4 DIABETES MELLITUS (SGD) | DOAP PATH 8.3 CYTOLOGYSTAINING | ||||
DAY 4 | CLINICAL POSTING | CM 13.1 Field visit on related to mental health | MI 8.10 SAMPLE COLLECTION(SGD) | PA 32.4 DIABETES MELLITUS (SGD) | PH 1.54 VACCINES AND THEIR USES | ||||
DAY 5 | CLINICAL POSTING | MI 8.6 BIOMEDICAL WASTE MANAGEMENT | PA 32.9 ADRENAL NEOPLASMS | DOAP - PH 4.2 DEMOSTRATE THE EFFECTS OF DRUGS ON BLOOD PRESSURE (VASOPRESSOR AND VASODEPRESSORS WITH APPROPRIATE BLOCKERS) USING COMPUTER AIDED LEARNING | DOAP - PH 4.2 DEMOSTRATE THE EFFECTS OF DRUGS ON BLOOD PRESSURE (VASOPRESSOR AND VASODEPRESSORS WITH APPROPRIATE BLOCKERS) USING COMPUTER AIDED LEARNING | ||||
DAY 6 | CLINICAL POSTING | SEMINAR -FORENSIC MEDICINE | |||||||
DAY 7 | |||||||||
NINENTH MONTH | DAY 1 | CLINICAL POSTING | IM 11.1 DIABETES MELLITUS | PH 1.55 NATIONAL HEALTH PROGRAMMES | MI 1.1 LAB DIAGNOSIS OF VIRAL INFECTIONS(SGD) | FM 2.2 NATURAL & UNNATURAL DEATHS | INTEGARTION WITH PATOLOGY | ||
DAY 2 | CLINICAL POSTING | Su 22.5 applied anatomy of parathyroid | PA 32.7 ADRENAL INSUFFICIENCY | MI 8.12 CONFIDENTIALITY PERTAINING TO PATIENT IDENTITY IN LABORATORY RESULTS(SGD) | MI 8.15 LAB DIAGNOSIS OF VIRAL INFECTIONS(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM18.1International Health-1 | SGD - PH 1.55 NATIONAL HEALTH PROGRAMMES | PA 32.8 CUSHINGS SYNDROME (SGD) | DOAP PATH 8.3 CYTOLOGYSTAINING | ||||
DAY 4 | CLINICAL POSTING | CM18.2 International Health -2 | MI 8.10 LAB DIAGNOSIS OF VIRAL INFECTIONS(SGD) | PA MEN SYNDROMES, PINEAL GLAND(SDL) | PH 1.56 BASICS OF GERIATRIC PHARMACOLOGY | ||||
DAY 5 | CLINICAL POSTING | MI 8.10 LAB DIAGNOSIS OF VIRAL INFECTIONS(SGD) | PA DEVELOPMENTAL ABNORMALITIES, OSTEOPOROSIS, FRACTURES | DOAP - PH 4.2 DEMOSTRATE THE EFFECTS OF DRUGS ON BLOOD PRESSURE (VASOPRESSOR AND VASODEPRESSORS WITH APPROPRIATE BLOCKERS) USING COMPUTER AIDED LEARNING | DOAP - PH 4.2 DEMOSTRATE THE EFFECTS OF DRUGS ON BLOOD PRESSURE (VASOPRESSOR AND VASODEPRESSORS WITH APPROPRIATE BLOCKERS) USING COMPUTER AIDED LEARNING | ||||
DAY 6 | CLINICAL POSTING | IA - PATH - 7 | PA DEVELOPMENTAL ABNORMALITIES, OSTEOPOROSIS, FRACTURES | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | SGD - PH 1.62 ANTISEPTICS AND DISINFECTANTS | MI 8.13 CHOOSE APPROPRIATE LABORATORY TEST IN THE DIAGNOSIS OF INFECTIVE DISEASES | FM 2.2 SUDDEN NATURAL DEATHS | INTEGRATED WITH MEDICINE | ||||
DAY 2 | CLINICAL POSTING | PA 33.1,33.2 OSTEOMYELITIS, BONE TUMORS (SGD) | PA 33.1,33.2 OSTEOMYELITIS, BONE TUMORS (SGD) | MI 7.1 SEXUALLY TRANSMITTED INFECTIONS REVISION | MI 8.15 INTERPRETATION OF LABORATORY RESULTS(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM10.9 Gender and health- Lecture | SGD - PH 1.61 DIETARY SUPPLEMENTS AND NEUTRACEUTICALS | PA 33.4 PAGET DISEASE (SGD) | PA 33.5 RHEUMATOID ARTHRITIS (SGD) | ||||
DAY 4 | CLINICAL POSTING | CM10.9 Gender and health- Group discussion | MI 8.15 OCULAR AND EAR INFECTIONS (SDL) | DOAP PA 23.2 BODY FLUIDS EXAMINATION | PH 1.16 5 ANTI - RHEUMATOID DRUGS & DRUGS FOR GOUT | ||||
DAY 5 | CLINICAL POSTING | Antenatal care and high risk obstetrics | PA SERONEGATIVE ARTHROPATHIES, TUMOR AND TUMOR LIKE CONDITIONS OF JOINTS | DOAP - PH 2.3 SETTING UP OF INTRAVENOUS DRIP IN A SIMULATED ENVIRONMENT | DOAP - PH 2.3 SETTING UP OF INTRAVENOUS DRIP IN A SIMULATED ENVIRONMENT | ||||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | MI3.1 GASTROINTESTINAL INFECTIVE SYNDROMES | PH 1.50 IMMUNOMODULATORS | MI 8.15 INTERPRETATION OF LABORATORY RESULTS(SGD) | FM 2.4 ORGAN TRANSPLANTATION & HUMAN ORGAN TRANSPLANT (AMENDMENT) ACT 2011(AETCOM) | INTEGRATED WITH MEDICINE | |||
DAY 2 | CLINICAL POSTING | Su 25.1 applied anatomy & investigations for breast disease | PA33.3 SOFT TISSUE TUMOURS (SGD) | MI 8.16 NATIONAL HEALTH PROGRAM | MI 1.1/8.15 IDENTIFICATIONOF BACTERIA - REVISION(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM10.8 Adolescent reproductive sexual health - | PH 1.50 IMMUNOSUPPRESSIVE THERAPY | PA NON NEOPLASTIC LESIONS OF SKIN(SDL) | DOAP PATH PA 34.4 TUMOURS OF SKIN | ||||
DAY 4 | CLINICAL POSTING | CM10.9 Gender issues and women empowerment | MI 8.15 INTERPRETATION OF LABORATORY RESULTS(SGD) | PA BENIGN AND PREMALIGNANT LESIONS OF SKIN | PH 1.51 OCCUPATIONAL AND ENVIRONMENTAL PESTICIDES , FOOD ADULTERANTS, POLLUTANTS | ||||
DAY 5 | CLINICAL POSTING | Assesment of fetal growth | PA 34.1 34.2 34.3 SCC , BCC, MELANOMA (SGD) | SGD PH 3.7 PREPARE LIST OF ESSENTIAL MEDICINES FOR A HEALTH CARE FACILITY | SGD PH 3.7 PREPARE LIST OF ESSENTIAL MEDICINES FOR A HEALTH CARE FACILITY | ||||
DAY 6 | CLINICAL POSTING | IA - CHEMOTHERAPY - ANTIVIRAL, ANTICANCER DRUGS | AT COM Module - 2.1, DEMONSTRATE ABILITY TO COMMUNICATE TO PATIENT IN A PATIENT, RESPECTFUL, NON THREATENING, NON JUDGEMENTAL AND EMPATHETIC MANNER | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | PH 1.53 HEAVY METALS AND CHELATING AGENTS (SDL) | MI 3.6 ACID PEPTIC DISEASE | FM 2.4 ORGAN TRANSPLANTATION & HUMAN ORGAN TRANSPLANT (AMENDMENT) ACT 2011(AETCOM) CONT.. | INTEGRATED WITH MEDICINE | ||||
DAY 2 | CLINICAL POSTING | Su 25.3 clinical features investigations & treatment of breast disease | PA CNS DEVELOPMENTAL DISEASES, INJURY | MI 8.1 ZOONOTIC INFECTIONS(SDL) | MI1.6 ANTIMICROBIAL SUSCEPTIBILITY TEST - REVISION(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM8.1Epidemiology of Emerging and Re - emerging Infections | SGD - PH 1.52 - DESCRIBE MANAGEMENT OF COMMON POISONING, INSECTICIDE, COMMON STINGS AND BITES | PA CNS EDEMA, ICT, MALFORMATIONS | DOAP PATH 35.3 ETIOLOGY OF MENINGITIS BASED ON CSF FINDINGS | ||||
DAY 4 | CLINICAL POSTING | CM10.8 Adolescent reproductive sexual health - GD | MI 8.1 COMMON VECTORS CAUSING ZOONOTIC DISEASES | PA PRION DISEASES | PH 1.13, 1.14 - ANS SGD | ||||
DAY 5 | CLINICAL POSTING | Teratogenesis | PA DEMYELINATING DISEASES OF CNS, DEGENERATIVE DISEASES OF CNS | SGD PH 2.2 OSPE-REVISON | SGD PH 2.2 OSPE-REVISON | ||||
DAY 6 | CLINICAL POSTING | IA VI / AETCOM module 2.3 describe and discuss the role of justice as aguiding principle in patient care | |||||||
DAY 7 | |||||||||
TENTH MONTH | DAY 1 | CLINICAL POSTING | IM 12.1 THYROID DYSFUNTION | PH 1.13, 1.14 - ANS SGD | MI 2.3 BLOOD STREAM INFECTIONS REVISION(SGD) | FM 2.5 MODES OF DEATH,COMA,ASPHYXIA & SYNCOPE | |||
DAY 2 | CLINICAL POSTING | SU 28.3 clinical features complications & principles of management of peritonitis | PA METABOLIC DISEASES OF BRAIN- GENETIC, TOXIC & ACQUIRED | MI 1.5 APPROPRIATE METHOD OF STERILISATION AND DISINFECTION IN SPECIAL SITUATIONS REVISION (SGD) | MI 1.1/8.15 LAB DIAGNOSIS OF FUNGAL INFECTIONS -REVISION(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM8.1 Programmes related to control of STD | PH 1.19 CNS - SGD | PA 35.2 CNS TUMOURS | DOAP PA 8.2 BASICS OF EXFOLIATIVE CYTOLOGY- TECHNIQUE AND STAINS USED | ||||
DAY 4 | CLINICAL POSTING | CM8.1 Bioterrorism -AGENTS and control | MI 1.9 VACCINES | PA CEREBROVASCULAR DISEASES | PH 1.19 CNS - SGD | ||||
DAY 5 | CLINICAL POSTING | USG in pregnancy | PA 22.1 ABO & RH GROUPING PA 22.6 TRANSFUSION REACTIONS (SGD) | PH 2.1 ,2.4 DRUG DOSAGE REVISION | PH 2.1 ,2.4 DRUG DOSAGE REVISION | ||||
DAY 6 | CLINICAL POSTING | IA - PATH - 8 | PA 22.1 ABO & RH GROUPING PA 22.6 TRANSFUSION REACTIONS (SGD) | ||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 10.1 AKI AND CKD | PH 1.18,1.21 CNS - SGD | MI 1.1,1.2,1.6,8.10 GENERAL BACTERIOLOGY REVISION | FM 2.6 PRRSUMPTION OF DEATH,SURVIVORSHIP | ||||
DAY 2 | CLINICAL POSTING | SU 30.5 clinical features investigations & treatment of hydrocele | PA 22.1 ABO & RH GROUPING PA 22.6 TRANSFUSION REACTIONS (SGD) | MI8.15IMMULOLOGY REVISION | MI 6.3 LAB DIAGNOSIS OF TUBERCULOSIS(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM8.1 AIDS -lecture | PH 1.26, 1.27,1.28 CVS - SGD | MI8.15IMMULOLOGY REVISION | DOAP PATH PRACTICALS REVISION | ||||
DAY 4 | CLINICAL POSTING | CM8.1 Hytadid disease | MI2.7, 8.15, 8.16 VIRAL INFECTIONS REVISION | PA 22.5 INFECTIONS TRANSMITED BY TRANSFUSION | PH 1.26, 1.27,1.28 CVS - SGD | ||||
DAY 5 | CLINICAL POSTING | Maternal pelvis | PA 36.1 RETINOBLASTOMA | SGD PH 3.1 , 3.2 PRESCRIPTION WRITING / AUDIT REVISION | SGD PH 3.1 , 3.2 PRESCRIPTION WRITING / AUDIT REVISION | ||||
DAY 6 | CLINICAL POSTING | II SATURDAY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 13.1 COMMON MALIGNANCY | PH 1.26, 1.27,1.28 CVS - SGD | MI 8.15MYCOLOGY CULTURE DISCUSSION (SGD) | FM 2.7 SUSPENDED ANIMATION | ||||
DAY 2 | CLINICAL POSTING | SU 28.7 applied anatomy & Pathophysiology of stomach | REVISION GENERAL PATHOLOGY | MI 8.5,8.6, HOSPITAL INFECTION CONTROL REVISION - REVISION(SGD) | IMMNOSEROLOGY REVISION(SGD) | ||||
DAY 3 | CLINICAL POSTING | CM8.1 Demonstration session on ORS | PH 1.36, 1.37, 1.39, 1.40 HORMONES - SGD | REVISION GENERAL PATHOLOGY | DOAP PATH PRACTICALS REVISION | ||||
DAY 4 | CLINICAL POSTING | CM8.2 Field visit -RNTCP unit | MI8.7, 8.8HOSPITAL INFECTION CONTROL REVISION - REVISION(SGD) | REVISION GENERAL PATHOLOGY | PH 1.36, 1.37, 1.39, 1.40 HORMONES - SGD | ||||
DAY 5 | CLINICAL POSTING | Fetal skull | REVISION RBC WBC WITH DOAP SESSION | DOAP - PH 4.1 ADMINISTER DRUGS THROUGH VARIOUS ROUTES IN A SIMULATED ENVIRONMENT USING MANNEQUINES - REVISION | SGD PH 4.2 CAL REVISION | ||||
DAY 6 | CLINICAL POSTING | IA - PHARMACOLOGY MODEL REVISION - THEORY | |||||||
DAY 7 | |||||||||
DAY 1 | CLINICAL POSTING | IM 21.1 POISONING | PH 1.43, 1.46 , 1.47, 1.48 - CHEMOTHERAPY SGD | IA - Microbiology - Model Practicals | |||||
DAY 2 | CLINICAL POSTING | Su 28.1 pathophysiology clinical features investigations & management of hernia | REVISION SYSTAMIC PATHOLOGY | MI1.1,8.15 FUNGAL INFECTIONS REVISION(SGD) | |||||
DAY 3 | CLINICAL POSTING | CM8.1 DOAP Session on ARI | PH 1.43, 1.46 , 1.47, 1.48 - CHEMOTHERAPY SGD | ||||||
DAY 4 | CLINICAL POSTING | CM8.1 Small group discussion on TB | MI3.1,3.2,8.15 PARASITIC INFECTIONSREVISION(SGD) | REVISION SYSTAMIC PATHOLOGY | PH 1.43, 1.46 , 1.47, 1.48 - CHEMOTHERAPY SGD | ||||
DAY 5 | CLINICAL POSTING | Fetal circulation | PRACTICAL REVISION | IA - PHARMACOLOGY MODEL REVISION - PRACTICALS | |||||
DAY 6 | CLINICAL POSTING | IA - Microbiology - Model Theory | |||||||
DAY 7 |
Date | Days | 8-9am | 9- 10 am | 10-11am | 11.15am - 12.15pm | 12.15pm - 1.15 | Lunch 1.15-2.00 | 2.00pm - 3.00pm | 03.00pm - 04.00pm |
---|---|---|---|---|---|---|---|---|---|
16.12.23 | Saturday | orientation | orientation | orientation | orientation | orientation | orientation | orientation | orientation |
18.12.23 | Monday | orientation | orientation | orientation | orientation | orientation | orientation | orientation | orientation |
19-12-23 | Tuesday | CP | CP | CP | PH 1.1 Principles of Pharmacology Pharmacotherapeutics (L1) | PA 1.1,1.2,1.3 INTRODUCTION TO PATHOLOGY -L | LUNCH | MI 1.1 Introduction to Microbiology | MI 1.1 Morphology of bacteria |
20-12-23 | Wednesday | CP | CP | CP | CM8.1,8.2,8.3 RABIES(L) | CM8.1,8.2,8.3 RABIES(L) | PA 2.1- CELL INJURY-L | PA 2.1 CELL INJURY-L | |
21-12-23 | Thursday | CP | CP | CP | PA 2.4 CELL DEATH NECROSIS -SGD | MI 1.1Microscopy | LUNCH | PH 1.4 PK-Absorption, Distribution (L1) | INTRODUCTION -PRACTICAL CLASS |
22-12-23 | Friday | CP | CP | CP | PH 1.4 PK-Absorption, Distribution (L1) | PH 1.3 Drug Formulations DDS (L1) | PA 2.4,2.7-APOPTOSIS-SGD | PRACTICALS- MICROSCOPY | |
23-12-23 | Saturday | AETCOM -MODULE 2.1 medicine | OG 2.1 Development and Anatomy of Female Reproductive Tract | FM1.1 FM1.2 Introduction to Forensic Medicine and Toxicology | MI1.1 Physiology of bacteria | MI 1.1 SPECIMEN COLLECTION AND TRANSPORT | LUNCH | PH 2.5 AETCOM-Bio Ethics | PH2.5 AETCOM- Bio Ethics |
24-12-23 | Sunday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
25-12-23 | Monday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
26-12-23 | Tuesday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
27-12-23 | Wednesday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
28-12-23 | Thursday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
29-12-23 | Friday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
30-12-23 | Saturday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
31-12-23 | Sunday | vacation | vacation | vacation | vacation | vacation | vacation | vacation | vacation |
01-01-24 | Monday | holiday | |||||||
02-01-24 | Tuesday | CP | CP | CP | PH 1.4 PK Biotransformation (L1) | PA 2.2- Mechanism of Cell injury-SGD | Lunch | MI 1.2 Staining techniques in detection of organisms | MI 1.1 Culture media |
03-01-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4 HIV/AIDS(L) | CM 8.1,8.3,8.4 HIV/AIDS(L) | Pathological calcification - PA2.5-L | Cell as a unit of health /disease-SDL | |
04-01-24 | Thursday | CP | CP | CP | PA 2.3 Intracellular accumulation-SGD | MI 1.1 Culture methods | LUNCH | PH 1.4 PK – Excretion (L1) | PATH PRACTICALS 4.4- ACUTE INFLAMMATION & cHRONIC INFLAMMATION -DOAP |
05-01-24 | Friday | CP | CP | CP | PH 1.5 Pharmacodynamics (L1) | PH 1.5 Pharmacodynamics (L1) | PA 2.5,2.7-Gangrene, cell ageing -SGD | PRACTICALS MICRO 1.2 GRAM STAINING | |
06-01-24 | Saturday | yoga | SU1.1 Describe Basic concepts of homeostasis, enumerate the metabolic changes in injury and their mediators. | FM1.3 FM1.4 Legal Procedures 1 | PA 2.6-CELLULAR ADAPTATIONS-SGD | PH 1.3Dosage Formulations | PH 2.5 AETCOM- Bioethics | PH 2.5 AETCOM- Bioethics | |
07-01-24 | Sunday | holiday | |||||||
08-01-24 | Monday | CP | CP | CP | OG 3.1 Physiology of Ovulation, Menstruation, Fertilization, Implantation and Gametogenesis. | MI 1.1 Identification of Bacteria | PH 2.1 Drug Formulations DDS (SGD/Practical1) | PH 2.1 Drug Formulations DDS (SGD/Practical1) | |
09-01-24 | Tuesday | CP | CP | CP | PH 1.9 Nomenclature of drugs(L1) | PA 4.1 ACUTE AND CHRONIC INFLAMMATION /EVENTS OF INFLAMMATION-L | Lunch | MI 1.1 Antimicrobial susceptibility testing | MI 1.1 Bacterial genetics |
10-01-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4 RICKETSSIAL INFECTIONS (L) | FM1.5 Legal Procedures 2 | LUNCH | PA 4.2- MEDIATORS OF INFLAMMATION-SGD | PA 4.2, MEDIATORS OF INFLAMMATION-SGD |
11-01-24 | Thursday | CP | CP | CP | PA 4.3- Chronic inflammation -SGD | MI 1.1 Overview of Bacterial Infections | PH 1.56 Pediatric & Geriatric Pharmacology (L1) | PRACTICAL PATHOLOGY-INTRODUCTION | |
12-01-24 | Friday | CP | CP | CP | PH 1.12 Dosage calculations children, elderly, Renal,Hepatic dysfunction (SGD1/Theory) | PH 1.12 Dosage calculations children, elderly, Renal,Hepatic dysfunction (SGD1/Theory) | PA 5.1 Tissue repair- L | PRACTICALS MICRO 1.2 GRAM STAINING | |
13-01-24 | Saturday | holiday | |||||||
14-01-24 | Sunday | holiday | |||||||
15-01-24 | Monday | holiday | |||||||
16-01-24 | Tuesday | holiday | |||||||
17-01-24 | Wednesday | holiday | |||||||
18-01-24 | Thursday | CP | CP | CP | PA 5.1-Wound healing-SGD | MI 1.1 Introduction to Virology | LUNCH | 1.63 Drug Regulations/ Drug Development & GCP ( L1) | PERIPHERAL SMEAR -PRACTICAL |
19-01-24 | Friday | CP | CP | CP | PH 1.6 Pharmacovigilance & ADR reporting Systems (L1) | PH 1.6 Pharmacovigilance & ADR reporting Systems (L1) | PA 6.1,6.2- EDEMA, HYPEREMIA, CONGESTION-SDL | PRACTICALS MICRO 1.2 GRAM STAINING | |
20-01-24 | Saturday | PANDEMIC MODULE 2.5 | IM1.3 RHEUMATIC FEVER | FM1.6 FM1.7 FM1.8 Legal Procedure 3 | PA 6.3-SHOCK -INT SESSION | PA 13.2-Anticoagulants in hematology-SDL | Lunch | PH 1.1 Clinical Pharmacology charts - I (SGD1/ Practical) | PH 2.5 pandemic-pharm new drug development |
21-01-24 | Sunday | ||||||||
22-01-24 | Monday | CP | CP | CP | IM3.1 ,3.2 DEFINITION OF PNEUMONIA AND ITS TYPES | MI 1.1 Introduction to Parasitology and lab diagnosis | PH 3.4 ADR REPORTING | PH 3.4 ADR REPORTING | |
23-01-24 | Tuesday | CP | CP | CP | PH 1.8 Drug Interactions (L1) | PA 6.4-THROMBOSIS-SGD | Lunch | MI Antimicrobial resistance-Integration with Pharm | Antimicrobial resistance-Integration with Pharm |
24-01-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4+CM 3.3 POLIO(L) | FM1.9 Legal Procedure 4 | PA 6.5,6.6-Embolism, infarction-SGD | PA6.5,6.6-embolism,infarction-SGD | |
25-01-24 | Thursday | ||||||||
26-01-24 | Friday | ||||||||
27-01-24 | Saturday | yoga | OG 4.1 Embryology of fetus, Anatomy and Physiology of placenta and Teratogenesis | FM1.10 FM1.11 Legal Procedure 5 | INTERNAL ASSESSMENT - 1 GENERAL MICROBIOLOGY | INTERNAL ASSESSMENT - 1 GENERAL MICROBIOLOGY | LUNCh | pandemic-cm | pandemic -infection control practices hand washing |
28-01-24 | Sunday | ||||||||
29-01-24 | Monday | CP | CP | CP | SU1.2 Describe the factors that affect the metabolic response to injury.. | MI 1.1 Epidemiological basis of Infectious Diseases | PH 2.3 Dosage calculations (DOAP1/Practical) | PH 2.3 Dosage calculations (DOAP1/Practical) | |
30-01-24 | Tuesday | CP | CP | CP | PH 1.2 EBM , TDM (L1) | PA 9.1 Principles and mechanism of immunity-SGD | Lunch | MI 1.1 Introduction to Mycology and lab diagnosis | MI 1.1 Normal human microbiata |
31-01-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4+CM 3.6,3.7,3.8 JE(L) | CM 8.1,8.3,8.4+CM 3.6,3.7,3.8 JE(L) | PA 9.2 Type 1 and 2 hypersensitivity reaction-SGD | PA 9.2 Type 1 and 2 hypersensitivity reaction-SGD | |
01-02-24 | Thursday | CP | CP | CP | PA 9.2 Type 3 and 4 HSR-SGD | MI 1.1 Sterilisation and disinfection | LUNCH | PH 1.60.1 to 1.60.3 Pharmacogenomics &PharmacoEconomics (L1) | Acute appendicitis - SGD (Practicals) |
02-02-24 | Friday | CP | CP | CP | PH 1.42 Chemo General principles (L1) | PH 1.42 Chemo sulfa & quinolones (L1) | PA 9.4- Autoimmunity-L | PRACTICALS MICRO 1.2 GRAM STAINING | |
03-02-24 | Saturday | yoga | SU2.1 Describe Pathophysiology of shock, types of shock & principles of resuscitation including fluid replacement and monitoring. | FM2.1 FM2.2 FM2.3 FM2.5 FM2.6 Death & Its causes | PA 9.5-SLE-SGD | pharmacology IA-1 GP | PA 2.4 AETCOM | PA 2.4 AETCOM | |
04-02-24 | Sunday | holiday | |||||||
05-02-24 | Monday | CP | CP | CP | IM autoimmune diseases | MI 1.8 Components of Immune system | PH 2.1 Dosage forms DOAP 1/ Practical | PH 2.1 Dosage forms DOAP 1/ Practical | |
06-02-24 | Tuesday | CP | CP | CP | PH 1.42.BETA LACTAMS (L1) | PA 9.7 OTHER AUTOIMMUNE DISORDERS-SGD | Lunch | MI 1.7 Immunity | MI 1.8 Antigen and antibody |
07-02-24 | Wednesday | CP | CP | CP | CM 8.1.8.3,8.4 EMERGING DISEASES & RE EMERGING DISEASES (L) | FM2.4 Medical Ethics & Laws | LUNCH | PA 9.3 Transplant rejection -SGD | PA 22.4 - Blood components-SDL |
08-02-24 | Thursday | CP | CP | CP | Immunodeficiency diseases-L | MI 1.8 Humoral immune response | PH 1.42.BETA LACTAMS (L1) | Reversible cell injury- Kidney (SGD)-Practicals | |
09-02-24 | Friday | CP | CP | CP | PH 1.43 Rational use of antimicrobials including ASP (SGD 1/THEORY) | PH 1.43 Rational use of antimicrobials including ASP (SGD 1/THEORY) | PA 3.1 Amyloidosis-SGD -Practical | PRACTICALS MICRO 1.2 ACID FAST STAINING | |
10-02-24 | Saturday | holiday | |||||||
11-02-24 | Sunday | holiday | |||||||
12-02-24 | Monday | CP | CP | CP | OG 5.1 Preconceptional counselling and screening and management of pre existing medical disorders | MI 1.8 Cell mediated immune response | PH 1.1 Clinical Pharmacology charts - I (SGD1/ Practical) | PH 1.1 Clinical Pharmacology charts - I (SGD1/ Practical) | |
13-02-24 | Tuesday | CP | CP | CP | PH 1.42 Aminoglycosides, Broad spectrum antibiotics (SGD1/Theory) | PA 11.1 Cytogenetic abnormalities in childhood-L | Lunch | INTERNAL ASSESSMENT GENERAL MICROBIOLOGY-II | INTERNAL ASSESSMENT GENERAL MICROBIOLOGY-II |
14-02-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4+CM 3.6,3.7,3.8 DENGUE(L) | CM 8.1,8.3,8.4+CM 3.6,3.7,3.8 DENGUE(L) | PA 11.1 Genetics- Lecture | PA 11.1 Genetics-L | |
15-02-24 | Thursday | CP | CP | CP | PA 10.4- Tuberculosis- Int session | MI 1.8,8.15 Antigen antibody reactions I | LUNCH | PH 1.47 Drugs for Kala azar(L1) | Granulation tissue, fatty liver- SGD Practicals |
16-02-24 | Friday | CP | CP | CP | PH 1.44 ATT drugs (L1) | PH 1.44 ATT drugs, MDR,XDR TB (SGD1) Integration with Chest medicine | PA 11.1 Genetics- Lecture | PRACTICALS MICRO 1.2 ACID FAST STAINING | |
17-02-24 | Saturday | AETCOM- OG | IM heart failure mgt | FM2.7 FM2.8 Post mortem changes 1 | IA -1, Chapter 1,2,3 | IA -1, Chapter 1,2,3 | Lunch | PH 1.47 Antiamoebic drugs (L1) | pandemic-micro |
18-02-24 | Sunday | ||||||||
19-02-24 | Monday | CP | CP | CP | SU2.2 Describe the clinical features of shock and its appropriate treatment. | MI 1.8,8.15 Antigen antibody reactions II | PH 1.45 MDR,XDR TB (L1) | PH 1.47 Antihelminthic drugs (L1) | |
20-02-24 | Tuesday | CP | CP | CP | PH 1.46 Drugs for leprosy- dermatology Integration (L1) | PA 11.1,11.3 -Other genetic disorders- L | Lunch | MI 1.8 Complement | MI 1.10 Hypersensitivity |
21-02-24 | Wednesday | CP | CP | CP | CM 3.1 AIR POLLUTION (SEMINAR) | FM2.9 Post mortem changes 2 | PA 11.1,11.3 Genetics- L | PA 11.1,11.3-Genetis- L | |
22-02-24 | Thursday | CP | CP | CP | PA 7.1 Define neoplasia, benign and malignant neoplasm | MI 1.10 Autoimmunity | PH 1.48 Drugs for STD and UTI (L1) | VIVA 1 | |
23-02-24 | Friday | CP | CP | CP | PH 1.47 drugs for malaria(L1) | PH 1.47 drugs for malaria(L1) | PA 7.2- Molecular basis of cancer I-SGD | PRACTICALS MICRO 1.2 ACID FAST STAINING | |
24-02-24 | Saturday | yoga | OG 6.1 Diagnosis of pregnancy, Clinical features and pregnancy tests | FM2.10 Post mortem changes 3 | MI 1.10 Immunodeficiency disorders | MI 1.11 Transplant and tumor immunity | LUNCh | pandemic-micro | pandemic -cm |
25-02-24 | Sunday | ||||||||
26-02-24 | Monday | CP | CP | CP | OG 5.2 Immunisation in pregnancy | MI 2.1,2.2 Acute Rheumatic fever | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | |
27-02-24 | Tuesday | CP | CP | CP | PH 1.48 Anti Viral, AntiRetroViral (L1) | PA 7.2- Molecular basis of cancer II-SGD | Lunch | MI 2.3,8.15 Infective endocarditis | MI 2.1,2.2,2.4 Blood stream infections |
28-02-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4+CM 3.6,3.7,3.8 MALARIA & FILARIA (L) | CM 8.1,8.3,8.4+CM 3.6,3.7,3.8 MALARIA & FILARIA (L) | PA 9.6 -HIV-Integrated session | PA 9.6 -HIV-Integrated session | |
29-02-24 | Thursday | CP | CP | CP | PA 7.3- Carcinogens-L | Fever of unknown origin | LUNCH | PH 1.48 Anti Viral, AntiRetroViral (L1) | CVC Liver, Lung- SGD -Practical |
01-03-24 | Friday | CP | CP | CP | PH 1.49 Anticancer drugs (L1) | PH 1.49 Anticancer drugs (L1) | PA 10.1-Malaria- Integrated session | Microbiology | |
02-03-24 | Saturday | yoga | SU2.3 Communicate and counsel patients and families about the treatment and prognosis of shock demonstrating empathy and care | FM2.11 FM2.12 FM2.13 FM2.14 Medicolegal autopsy 1 | PA 10.3 Leprosy-L | Pharmacology IA- 2 chemo-1 | PA 2.4 AETCOM | PA 2.4 AETCOM | |
03-03-24 | Sunday | holiday | |||||||
04-03-24 | Monday | CP | CP | CP | anemia | MI 2.5,8.16 Anemia agent- Malaria | PH 2.3 IV Drip setting DOAP1/Practical | PH 2.3 IV Drip setting DOAP1/Practical | |
05-03-24 | Tuesday | CP | CP | CP | PH 1.48 Anti fungal drugs (L1) | PA10.4 Syphilis-L | Lunch | MI 2.5,8.16 Anemia agent- Malaria | MI 3.1 Anemia agent- Hookworm |
06-03-24 | Wednesday | CP | CP | CP | INTERNAL ASSESSMENT -I | FM 2.15 Medicolegal autopsy 2 | LUNCH | PA 7.2- Angiogenesis, invasion, metastasis, evasion of host defenses-SGD | PA 7.2- Angiogenesis, invasion, metastasis, evasion of host defenses-SGD |
07-03-24 | Thursday | CP | CP | CP | PA 9.3- Transplant rejection-SDL | MI 2.6,8.15 Anemia agent- Leishmania | PH 1.50 Immunomodulators (L1) | Organization of thrombus, atheroma- SGD(Practical) | |
08-03-24 | Friday | CP | CP | CP | PH 1.14 Intro to ANS (L1) | PH 1.14 Cholinergic Transmission & Drugs (L1) | PA 7.4 Paraneoplastic syndrome- SGD | Microbiology | |
09-03-24 | Saturday | holiday | |||||||
10-03-24 | Sunday | holiday | |||||||
11-03-24 | Monday | CP | CP | CP | OG 7.1 Maternal changes in pregnancy | MI 2.6,8.15 Trypanosoniasis | PH 3.1 Prescription writing (Skill station SGD1/Practical) | PH 3.1 Prescription writing (Skill station SGD1/Practical) | |
12-03-24 | Tuesday | CP | CP | CP | PH 1.14 AntiCholinergic Drugs (L1) | PA 12.2 PEM -L | Lunch | MI 3.4,8.15 Leptospira | MI 8.1 Brucella,Borrelia |
13-03-24 | Wednesday | CP | CP | CP | CM 3.1WATER POLLUTION (SEMINAR) | CM 3.1WATER POLLUTION (SEMINAR) | PA 12.1 - Tobacco and alcohol-SGD | PA 12.1 - Tobacco and alcohol-SGD | |
14-03-24 | Thursday | CP | CP | CP | PA 12.3 Obesity- Int session | MI 1.1,8.15 Viral hemorrhagic fever | LUNCH | PH 1.14 AntiCholinergic Drugs (L1) | Capillary and cavernous hemangioma- SGD Practical |
15-03-24 | Friday | CP | CP | CP | PH 1.13 Adrenergic Drugs (L1) | PH 1.13 Adrenergic Drugs (L1) | Neonatal RDS, Necrotizing enterocolitis-SGD | Microbiology | |
16-03-24 | Saturday | PANDEMIC MODULE 2.5 | IM 9.1 DEFIN AND CLASSIFY ANEMIA | FM2.16 FM2.17 Medicolegal autopsy 3 | IA 2 Hemodynamic disorders, Genetics | IA2- Hemodynamic disorders, Genetics | Lunch | PH 1.13 Adrenergic Drugs (L1) | pandemic - cm |
17-03-24 | Sunday | holiday | |||||||
18-03-24 | Monday | CP | CP | CP | SU3.1 Describe the Indications and appropriate use of blood and blood products and complications of blood transfusion. | MI 1.1,8.15 Rickettsial infections | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | |
19-03-24 | Tuesday | CP | CP | CP | PH 1.13 Anti Adrenergic Drugs (L1) | PA 11.3 Perinatal infections, fetal hydrops-SGD | Lunch | INTERNAL ASSESSMENT - IMMUNOLOGY | INTERNAL ASSESSMENT - IMMUNOLOGY |
20-03-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4 ARI(L) | FM2.18 Medicolegal autopsy 4 | PA 11.3 Cystic fibrosis , SIDS -SGD | VIVA 2 | |
21-03-24 | Rickettsial Infections | CP | CP | CP | PA 11.2 Tumors of infancy-SGD | MI 1.1,8.15 Systemic mycoses I-Candida | PH 1.13 Anti Adrenergic Drugs (L1) | LIPOMA, ACTINOMYCOSIS -PRACTICAL-SGD | |
22-03-24 | Friday | CP | CP | CP | PH 1.13 Anti Adrenergic Drugs (L1) | PH 1.15 Sketal Muscle relaxing agents (L1) | General principles of Microbial infections | Microbiology | |
23-03-24 | Saturday | yoga | OG 8.1 Antenatal Care | FM2.19 Anaesthetic & Operative death | INTEGRATED HIV/AIDS | INTEGRATED HIV/AIDS | LUNCh | pandemic-cm | pandemic-cm |
24-03-24 | Sunday | holiday | |||||||
25-03-24 | Monday | CP | CP | CP | OG 9.1 Etiology, Diagnosis and Management of Abortion | MI 1.1,8.15 Systemic mycoses - II | PH 4.2 CAL (SGD1/ Practical) | PH 4.2 CAL (SGD1/ Practical) | |
26-03-24 | Tuesday | CP | CP | CP | PH 1.17 Local Anaesthetics (L1) | PA 10.4 Viral infections- seminar/SDL | Lunch | MI 3.1 Diarrhoea and gastroenteritis-Introduction | MI 3.1 Escherichia coli |
27-03-24 | Wednesday | CP | CP | CP | CM 8.1,8.3,8.4 HEPATITIS (L) | CM 8.1,8.3,8.4 HEPATITIS (L) | PA 10.4 Bacterial ,fungal and parasitic infestations-SDL/Seminar | PA 10.4 Bacterial ,fungal and parasitic infestations-SDL/Seminar | |
28-03-24 | Thursday | CP | CP | CP | Air pollution -PA 12.1, SDL/Seminar | MI 3.1 Vibrio Cholera | LUNCH | PH 1.26 RAAS (SDL) | Squamous cell carcinoma- SGD-Practicals |
29-03-24 | Friday | holiday | |||||||
30-03-24 | Saturday | AETCOM MODULE 2.1 medicine | SU3.3 Counsel patients and family/ friends for blood transfusion and blood donation. | FM2.20 FM2.21 Asphyxia 1 | MI 3.2 NTS and Shigella | PH 1.26 RAAS (SDL) | PH5.1 AETCOM Convince a patient to go to authorized medical practitioner | PH 5.2AETCOM Communicating the diagnosis and Drug Therapy For Tuberculosis | |
31-03-24 | Sunday | holiday | |||||||
01-04-24 | Monday | CP | CP | CP | IM dyslipidemia | MI 3.5 Food poisoning | PH 4.2 CAL (SGD1/ Practical) | PH 4.2 CAL (SGD1/ Practical) | |
02-04-24 | Tuesday | CP | CP | CP | PH 1.28 Angina,MI,PVD INTEGRATION (L1) | PA 27.1- ATHEROSCLEROSIS - L | Lunch | MI 3.5 Clostridium botulinum and Clostridium difficile | MI 3.5 Clostridium perfringens |
03-04-24 | Wednesday | CP | CP | CP | CM 3.7,3.8 MEDICAL ENTOMOLOGY-PART 1(L) | CM 3.7,3.8 MEDICAL ENTOMOLOGY-PART 1(L) | PA 27.2 ANEURYSM - L | PA 27.2 ANEURYSM - L | |
04-04-24 | Thursday | CP | CP | CP | Hypertension , hypertensive heart disease SDL | MI 3.5 Staphylococcus aureus | LUNCH | PH 1.28 Angina,MI,PVD (L1) | PA 19.5 GROSS & MICROSCOPIC FEATURES - HODGKIN LYMPHOMA -DOAP |
05-04-24 | Friday | CP | CP | CP | PH 1.27 Antihypertensives- Integration with GM- (L1) | PH 1.27 Antihypertensives- (SGD1Theory) | vasculitis , blood vessel disorders (SGD) | Microbiology | |
06-04-24 | Saturday | yoga | SU5.1 Describe normal wound healing and factors affecting healing. | FM2.22 FM2.23 Asphyxia 2 | PA27.3 congenital heart disease (SGD) | Pharmacology IA-3 CHEMO-2 | MI AETCOM | MI AETCOM | |
07-04-24 | Sunday | holiday | |||||||
08-04-24 | Monday | CP | CP | CP | OG 10.2 Appropriate use of Blood and Blood Products in pregnancy | MI 3.1,3.6 Diarrhoea causing Agents - Campylobacter,H.pylori,Bacillus cereus | PH 3.1 Prescription writing (Skill station SGD1/Practical) | PH 3.1 Prescription writing (Skill station SGD1/Practical) | |
09-04-24 | Tuesday | holiday | |||||||
10-04-24 | Wednesday | CP | CP | CP | CM 3.1 NOISE POLLUTION &EFFECTS OF RADIATION (SEMINAR) | FM2.24 FM2.25 Thermal Injuries | LUNCH | PA 27.4 valvular heart disease , RHD -L | Cardiovascular diseases in syphilis -SDL-PA 27.10 |
11-04-24 | Thursday | holiday | |||||||
12-04-24 | Friday | CP | CP | CP | PH 1.27 Antihypertensives- (SGD1Theory) | PH 1.27 Antihypertensives- (SGD1Theory) | PA 27.6-INFECTIVE ENDOCARDITIS-SGD | Microbiology | |
13-04-24 | Saturday | holiday | |||||||
14-04-24 | Sunday | holiday | |||||||
15-04-24 | Monday | CP | CP | CP | PA5.1 Define and describe the process of repair and regeneration including wound healing and its types | MI 3.1 Intestinal Amoebiasis and Giardiasis | PH 3.2 CHEMO- PA SGD1/ Practical | PH 3.2 CHEMO- PA SGD1/ Practical | |
16-04-24 | Tuesday | CP | CP | CP | PH 1.24 Diuretics & Antidiuretics (SDL) | PA 27.7-PERICARDITIS, PERICARDIAL EFFUSION-L | Lunch | INTERNAL ASSESSMENT - IV CVS AND BSS | INTERNAL ASSESSMENT - IV CVS AND BSS |
17-04-24 | Wednesday | CP | CP | CP | CM 14.1,14.3 BIOMEDICAL WASTE MANAGEMENT (SEMINAR) | CM 14.1,14.3 BIOMEDICAL WASTE MANAGEMENT (SEMINAR) | PA27.5 IHD, Acute coronary syndromes-Integrated session | PA 27.5 IHD, Acute coronary syndromes- Integrated session | |
18-04-24 | Thursday | CP | CP | CP | PA27.9-Cardiomyopathy, cardiac tumors-L | MI 3.1 Coccidian parasites | LUNCH | PH 1.24 Diuretics & Antidiuretics (SDL) | Bronchiectasis- SGD(Practical) |
19-04-24 | Friday | CP | CP | CP | PH 1.29 Heart Failure (L1) | PH 1.30 Antiarrhythmias drugs (L1) | Election -holiday | Microbiology | |
20-04-24 | Saturday | AETCOM - sur | IM5.1 BILIRUBIN METABOLISM | Starvation FM2.26 | Physical examination of urine-Lecture | Physical examination of urine-Lecture | Lunch | PH 1.30 Antiarrhythmias drugs (SDL) | PH 5.2 AETCOM Drug complaince for hypertension |
21-04-24 | Sunday | holiday | |||||||
22-04-24 | Monday | CP | CP | CP | protozoal infections | Clostridium difficile,perfringens, Botulism | PH 3.2 CHEMO- PA SGD1/ Practical | PH 3.2 CHEMO- PA SGD1/ Practical | |
23-04-24 | Tuesday | CP | CP | CP | PH 1.25 Coagulants & Anticoagulants(L1) | Chemical examination of urine-I (SGD) | Lunch | Lab diagnosis of Food Poisoning | camphylobacter, V.parahemolyticus,B.cereus, H.pylori |
24-04-24 | Wednesday | CP | CP | CP | CM 3.5 HOUSING STANDARDS (SEMINAR) | FM2.27 Infanticide 1 | IA -3 | IA-3 | |
25-04-24 | Thursday | CP | CP | CP | ARDS,ALI, PULMONARY EDEMA-SGD | Viral Gastroenteritis | PH 1.25 Coagulants & Anticoagulants(L1) | Fibroadenoma, ascitic fluid positive for malignancy-SGD practical | |
26-04-24 | Friday | CP | CP | CP | PH 1.25 Fibrinolytics & Antifibrinolytics (L1) | PH 1.25 Fibrinolytics & Antifibrinolytics (L1) | Chemical examination of urine-II (SGD) | Microbiology | |
27-04-24 | Saturday | yoga | OG 12.2 Anemia in Pregnancy | FM2.28 Infanticide 2 | microbiology | intestinal Amoebiasis,giardiasis,coccidian parasites | LUNCh | pandemic- micro | Pandemic CM |
28-04-24 | Sunday | holiday | |||||||
29-04-24 | Monday | CP | CP | CP | MI1.4 Classify and describe the different methods of sterilization and disinfection. Discuss the application of the different methods in the laboratory, in clinical and surgical practice | Intesinal Cestode infections D.latum,H.nana,taenia | Pharmacology | Pharmacology | |
30-04-24 | Tuesday | CP | CP | CP | PH 1.25 Antiplatelets (L1) | PA26.5 Pneumoconiosis- lecture | Lunch | Intestinal Trematode infections f.buski,s.mansoni,s.japonicum | Intestinal Nematode infections Trichuris,Enterobius,Ascaris,Strongyloides,Hookworm |
01-05-24 | Wednesday | ||||||||
02-05-24 | Thursday | CP | CP | CP | Practical assessment revision (SGD) | Lab Diagnosis of Diarrhoea | LUNCH | PH 3.4.1 - 3.4.8 To Recognise and report ADR(SGD/practical) | PAP ESTROGENIC, PROGESTEROGENIC PHASE- PRACTICAL |
03-05-24 | Friday | CP | CP | CP | PH 1.13.1 - 1.15.21 | ANS & PNS(SGD/Theory) | COPD-EMPHYSEMA, CHRONIC BRONCHITIS-Lecture PA 26.3 | Microbiology | |
04-05-24 | Saturday | yoga | SU6.1 Define and describe the aetiology and pathogenesis of surgical Infections | FM2.29 Legal Procedure | INFECTIOUS DISEASES TRANSMITTED BY BLOOD TRANSFUSION-SDL | PH 3.5.1 - 3.5.5 P Drug (SGD/Practical) | PH AETCOM ADR reported by patient | PH convince the parent for iv cannulation to child | |
05-05-24 | Sunday | holiday | |||||||
06-05-24 | Monday | CP | CP | CP | ulcer mgt | Infective Syndromes of Hepatobiliary system, Yellow Fever | PH 4.1 Intravenous route of administration (DOAP) | ||
07-05-24 | Tuesday | CP | CP | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 |
08-05-24 | Wednesday | CP | CP | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 |
09-05-24 | Thursday | CP | CP | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 |
10-05-24 | Friday | CP | CP | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 |
11-05-24 | Saturday | ||||||||
12-05-24 | Sunday | ||||||||
13-05-24 | Monday | CP | CP | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 |
14-05-24 | Tuesday | CP | CP | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 |
15-05-24 | Wednesday | CP | CP | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 | PCT -1 |
16-05-24 | Thursday | CP | CP | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
17-05-24 | Friday | CP | CP | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
18-05-24 | Saturday | PANDEMIC MODULE 2.5 | coagulation disorders | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
19-05-24 | Sunday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
20-05-24 | Monday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
21-05-24 | Tuesday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
22-05-24 | Wednesday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
23-05-24 | Thursday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
24-05-24 | Friday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
25-05-24 | Saturday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
26-05-24 | Sunday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
27-05-24 | Monday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
28-05-24 | Tuesday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
29-05-24 | Wednesday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
30-05-24 | Thursday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
31-05-24 | Friday | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION | VACATION |
01-06-24 | Saturday | yoga | PA8.1 Describe the diagnostic role of cytology and its application in clinical care | FM2.33 FM2.34 Mass Disaster | Bronchial asthma and bronchiectasis- PA26.3 | PH 4.2.1-4.2.5 DPL | PA 2.8 AETCOM | PA 2.8 AETCOM | |
02-06-24 | Sunday | holiday | |||||||
03-06-24 | Monday | CP | CP | CP | IM5.4 EPIDEMIOLOGY OF VIRAL HEPATITIS | lab diagnosis of hepatitis | PH 2.3.1-2.3.8 IV DRIP SETTING- SGD2/ Practical | ||
04-06-24 | Tuesday | CP | CP | CP | PH 1.35.1-1.35.8 Drugs affecting blood formation(SGD1/Theory) | Restrictive lung disease and pulmonary vascular disorders | Lunch | staphylococcus infections | trematode infections of hepatic system |
05-06-24 | Wednesday | CP | CP | CP | CM 3.4 SOLID WASTE MANAGEMENT (SEMINAR) | FM2.35 Medicolegal Autopsy | LUNCH | PA 26.1, PA26.2 PNEUMONIA , LUNG ABSCESS-sgd | PA 26.1, PA26.2 PNEUMONIA , LUNG ABSCESS-SGD |
06-06-24 | Thursday | CP | CP | CP | PA 24.1, ORAL & SALIVARY GLAND TUMORS-LECTURE | Streptococcal infection | PH 1.33.1-1.33.7 Drugs for cough (SGD1 Theory) | pathology | |
07-06-24 | Friday | CP | CP | CP | PH 1.32 Bronchial Asthma & COPD-(L1) | PH 1.32 Bronchial Asthma & COPD-Integn.with Chest Medicine (L1) | DISEASES OF ESOPHAGUS-LECTURE | Microbiology | |
08-06-24 | Saturday | holiday | |||||||
09-06-24 | Sunday | holiday | |||||||
10-06-24 | Monday | PTA | PTA | PTA | PTA | gas gangrene | PTA | PH 1.3.1-1.3.5 Special drug delivery system | PTA |
11-06-24 | Tuesday | CP | CP | CP | PH 1.34Antiemetics & Prokinetics (L1) | PA24.2,24.3- PEPTIC ULCER DISEASE, Lecture | Lunch | cutaneous viral infections | anthrax , non veneral trepanomatoses |
12-06-24 | Wednesday | CP | CP | CP | CM 3.7,3.8 INTEGRATED VECTOR MANAGEMENT(L) | CM 3.7,3.8 INTEGRATED VECTOR MANAGEMENT(L) | PA 24.4- CARCINOMA OF STOMACH-LECTURE | PA 24.4- CARCINOMA OF STOMACH-LECTURE | |
13-06-24 | Thursday | CP | CP | CP | PA24.5, ULCERATIVE LESIONS OF SMALL AND LARGE INTESTINE, TB, TYPHOID, AMEBIASIS - SGD | pandemic module | LUNCH | PH 1.34 Drugs for constipation, Diarrhoea,( SGD1/Theory) | PATH PRACTICALS Melanoma |
14-06-24 | Friday | CP | CP | CP | PH 1.34 APD & GERD integration with Microbiology (SGD1/Theory) | PH 1.34 APD & GERD integration with Microbiology (SGD1/Theory) | CHARM - OD | Microbiology | |
15-06-24 | Saturday | PTA | PTA | PTA FM3.2 Identification | CHARM | CHARM | Lunch | PTM | pandemic-cm |
16-06-24 | Sunday | holiday | |||||||
17-06-24 | Monday | ||||||||
18-06-24 | Tuesday | CP | CP | CP | PH 1.34 APD & GERD integration with Microbiology (SGD1/Theory) | POLYPS OF INTESTINE - LECTURE | Lunch | ACTINOMYCOSIS , NOCARDIOSIS | Pox Virus, V-Z,parvo virus |
19-06-24 | Wednesday | CP | CP | CP | FM3.3 FM3.4 FM3.5 FM3.6 Mechanical injuries 1 | PA 24.6 INFLAMMATORY BOWEL DIASEASE - SGD | PA 24.6 INFLAMMATORY BOWEL DIASEASE - SGD | ||
20-06-24 | Thursday | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS |
21-06-24 | Friday | CP | CP | CP | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | |
22-06-24 | Saturday | yoga | OG 12.3 Diabetes in pregnancy | Mechanical injuries 2 FM3.7 | CHEMFEST/SPORTS | CHEMFEST/SPORTS | LUNCh | CHEMFEST/SPORTS | CHEMFEST/SPORTS |
23-06-24 | Sunday | holiday | |||||||
24-06-24 | Monday | CP | CP | CP | meningitis mgt | CHEMFEST/SPORTS | CHEMFEST/SPORTS | CHEMFEST/SPORTS | |
25-06-24 | Tuesday | CP | CP | CP | PH 1.34.24-1.34.26 IBD | MALABSORPTION SYNDROME -LECTURE | Lunch | LEPROSY | MEASLES,RUBELLA,COXSACKIE |
26-06-24 | Wednesday | CP | CP | CP | INTERNAL ASSESSMENT -II | INTERNAL ASSESSMENT -II | PA 25.3 VIRAL HEPATITIS - INTERGRATED - class cancelled ( mentor mentee meeting) | PA 25.3 VIRAL HEPATITIS - INTERGRATED, class cancelled - mentor mentee meeting | |
01-07-24 | Monday | CP | CP | CP | stroke | dracunculiasis,trichenellosis,cutaneous larva migrans | PH 2.2ORS (SGD1/ Practical) | PH 2.2ORS (SGD1/ Practical) | |
27-06-24 | Thursday | CP | CP | CP | PA 25.1 JAUNDICE, AUTOIMMUNE CHOLANGIOPATHIES, STRUCTURAL ANOMALIES OF BILIARY TREE - SGD | cutaneous leishmaniasis,filariasis | LUNCH | PH 1.16 5-HT antagonist - Drug therapy of migraine(L1) | PATH PRACTICALS GASTRIC ULCER |
28-06-24 | Friday | CP | CP | CP | Tamil mandram | Tamil mandram | Tamil mandram | Tamil mandram | |
29-06-24 | Saturday | Yoga | OG 12.1 Hypertensive Disorders in pregnancy | Mechanical injuries 3 FM3.8 | Tamil mandram | Tamil mandram | Tamil mandram | Tamil mandram | |
30-06-24 | Sunday | holiday | |||||||
02-07-24 | Tuesday | CP | CP | CP | PH 1.19 Sedatives-hypnotics/Anxiolytics (L1) | Carcinoma colon-L PA24.6 | Lunch | Superficial & S.C Mycosis - P. marneffi, Candidiasis | Infective syndromes of Respiratory tract Bacterial Pharyngitis - Streptococcus |
03-07-24 | Wednesday | CP | CP | CP | CM8.1,8.3,8.4 CHALLENGES FACED IN PREVENTION OF OF EMERGING &RE-EMERGING INFECTION | CM8.1,8.3,8.4 CHALLENGES FACED IN PREVENTION OF OF EMERGING &RE-EMERGING INFECTION | Internal assessment 4 | Internal assessment 4 | |
04-07-24 | Thursday | CP | CP | CP | PA 25.2,25.5 - hepatic failure, portal hypertension -L | Bacterial Pharyngitis - Diphtheria | LUNCH | PH 1.19 Antipsychotic drugs (L1) | PATH PRACTICAL- CIRRHOSIS, METS NODE, HCC CHART |
05-07-24 | Friday | CP | CP | CP | PH 1.18 General Anaesthetics Integration with Anaesthesia (L1) | PH 1.18 General Anaesthetics Integration with Anaesthesia (L1) | PA 25.4 ALD, NAFLD, CIRRHOSIS (SGD) | bacterial culture - e.coli, klebsiella, staphylococcus aureus, proteus (SGD) | |
06-07-24 | Saturday | yoga | SU 6.2 Enumerate Prophylactic and therapeutic antibiotics Plan appropriate management | FM3.9 Mechanical injuries 4 | inherited liver diseases-L | Pharmacology IA-6 RS ,GIT | PA 2.8 AETCOM | PA 2.8 AETCOM | |
07-07-24 | Sunday | holiday | |||||||
08-07-24 | Monday | CP | CP | CP | OG 13.1 physiology &Mechanism of Labour | Pneumococcus, H.Influenza | PH 3.5 P-drug (SGD1/ Practical) | PH 3.5 P-drug (SGD1/ Practical) | |
09-07-24 | Tuesday | CP | CP | CP | PH 1.19 Antipsychotic drugs (L1) | Tumors of liver -L | Lunch | Tuberculosis INTEGRATED LECTURE | Tuberculosis INTEGRATED LECTURE |
10-07-24 | Wednesday | CP | CP | CP | CM8.1,8.3,8.4,8.5 COVID 19 SEMINAR | FM3.10 Mechanical injuries 5 | LUNCH | Diseases of gall bladder- SGD | PATH PRACTICAL - MELANOMA, CARCINOMA COLON, GASTRIC ULCER |
11-07-24 | Thursday | CP | CP | CP | PA 32.6-Diseases of pancreas - lecture | Non Tuberculous Mycobacteria | PH 1.19 Parkinsonism – Drugs for Neurodegenerative disorders (L1) | PATH PRACTICAL - CPN,RCC | |
12-07-24 | Friday | CP | CP | CP | PH 1.19 Antidepressants Antimaniac drugs (L1) | PH 1.19 Antidepressants Antimaniac drugs (L1) | PA 28.5 glomerulonephritis | bacterial culture - e.coli, klebsiella, staphylococcus aureus, proteus (SGD) | |
13-07-24 | Saturday | holiday | |||||||
14-07-24 | Sunday | holiday | |||||||
15-07-24 | Monday | CP | CP | CP | SU 14.1 Describe Aseptic techniques, sterilization and disinfection. | Atypical Pneumonia | Pharmacology | Pharmacology | |
16-07-24 | Tuesday | CP | CP | CP | PH 1.19 Anti Epileptic Drugs (SGD1/Theory) | nephrotic syndrome -MCD,MN,FSGS,MPGN-L | Lunch | PERTUSSIS | non fermenting -pseudomona, acinetobacter, burkholderia |
17-07-24 | Wednesday | ||||||||
18-07-24 | Thursday | CP | CP | CP | PA28.6,28.7 IgA nephropathy, alports syndrome -sgd | myxovirus infections - influenza and parainfluenza | LUNCH | PH 1.19 Anti Epileptic Drugs (SGD1/Theory) | PATH PRACTICAL - WILMS TUMOR, TERATOMA |
19-07-24 | Friday | CP | CP | CP | PH 1.19 Opioid Analgesics & Antagonists (L1) | PH 1.19 Opioid Analgesics & Antagonists (L1) | PA28.8,28.9-ATN, TUBULAR INTERSTITIAL DISEASE - SGD | immunoserology- ASO , CRP, RF | |
20-07-24 | Saturday | PANDEMIC MODULE 2.5 | IM12.1 EPIDEMIOLOGY AND PATHOGENESIS OF THYROID DYSFUNCTION | FM3.11 FM3.12 Regional Injuries | IA5 | IA5 | Lunch | PH 1.23 Drug Deaddiction -SGD1 | PH 2.5 Discuss ethical aspects of clincal trials in pandemic |
21-07-24 | Sunday | holiday | |||||||
22-07-24 | Monday | CP | CP | CP | SU 14.2 Describe Surgical approaches, incisions and the use of appropriate instruments in Surgery in general. | Corona virus infections including COVID-19 | PH 3.3 DPL- SGD1/ Practical | PH 3.3 DPL- SGD1/ Practical | |
23-07-24 | Tuesday | CP | CP | CP | PH 1.22 Drugs of Abuse INTEGRATION with PSYCHIATRY (SGD1/Theory) | PA28.10- CPN ,REFLUX NEPHROPATHY -SGD | Lunch | Miscellaneous viral infections | Parasitic infections |
24-07-24 | Wednesday | CP | CP | CP | CM 19.1,19.2,19.3 VACCINES IN DISEASE CONTROL | FM3.13 Sexual Offences 1 | PA 28.11 vascular diseases of kidney-L | viva 3 | |
25-07-24 | Thursday | CP | CP | CP | PA 28.12 cystic diseases of kidney-SGD | Fungal infections-Zygomycosis,Aspergillosis | PH 1.20 Alcohol (SGD1/Theory) | PATH PRACTICAL - LEIOMYOMA, PAP HSIL | |
26-07-24 | Friday | CP | CP | CP | PH 1.21 Methanol and Ethanol poisoning(SGD1/Theory) | PH 1.21 Methanol and Ethanol poisoning(SGD1/Theory) | PA 28.13 renal stone (SGL) | immunoserology- ASO , CRP, RF | |
27-07-24 | Saturday | yoga | FM3.14 Sexual Offences 2 | INTERNAL ASSESSMENT-VI | INTERNAL ASSESSMENT-VI | LUNCh | pandemic-micro | pandemic -cm | |
28-07-24 | Sunday | holiday | |||||||
29-07-24 | Monday | CP | CP | CP | IM10.2 ACUTE RENAL FAILURE | Infective syndromes of central nervous system | PH 3.5 P-drug (SGD1/ Practical) | PH 3.5 P-drug (SGD1/ Practical) | |
30-07-24 | Tuesday | CP | CP | CP | PH 1.37 Pituitary hormones (L1) | PA 28.14 renal tumors -SGD | Lunch | Acute bacterial meningitis: N.meningitidis, S. pneumoniae, S.agalactiae, H.influenzae, Listeria | Chronic bacterial meningitis: Tubercular meningitis, spirochaetal meningitis, lyme disease and others |
31-07-24 | Wednesday | CP | CP | CP | CM 19.5 ROUTINE VACCINATION DURING PANDEMIC(L) | CM 19.5 ROUTINE VACCINATION DURING PANDEMIC(L) | PA 28.16 UROTHELIAL TUMORS- INTERGRATED SESSION | PA 28.16 UROTHELIAL TUMORS- INTERGRATED SESSION | |
01-08-24 | Thursday | CP | CP | CP | PA 29.1 testicular tumors-sgd | Tetanus | LUNCH | PH 1.36 Osteoporosis (SGD1/Theory) | PATH PRACTICALS - endometrium proliferative and secretory phase- sgd |
02-08-24 | Friday | CP | CP | CP | PH 1.38 Corticosteroids (L1) | PH 1.38 Corticosteroids (L1) | PA 29.2 carcinoma penis- SGD | Microbiology | |
03-08-24 | Saturday | yoga | SU 15.1 Describe classification of hospital waste and appropriate methods of disposal. | FM3.15 FM3.16 Sexual Offences 3 | PA carcinoma prostate, bph, prostatitis- lecture | Pharmacology IA-7 Autacoids | MI AETCOM | MI AETCOM | |
04-08-24 | Sunday | holiday | |||||||
05-08-24 | Monday | CP | CP | CP | IM10.5 CHRONIC RENAL FAILURE | Viral meningitis and viral myelitis: Poliomyelitis, coxsackievirus | PH 3.4 ADR REPORTING | PH 3.4 ADR REPORTING | |
06-08-24 | Tuesday | CP | CP | CP | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | Local holiday | Lunch | Viral Encephalitis and Encephalopathy-1 Rabies, HSV encephalitis | Viral Encephalitis and Encephalopathy-2 Arboviral encephalitis (J.E & West Nile), Nipah and Hendra, slow virus and prion disease, |
07-08-24 | Wednesday | CP | CP | CP | CM 6.4 SAMPLING METHODS | FM3.17 Sexual Offences 4 | LUNCH | PA 25.3,PA25.6 -viral hepatitis integrated session | PA 30.1,30.6- carcinoma cervix ,cervicitis- sgd |
08-08-24 | Thursday | CP | CP | CP | PA 30.7,30.8,30.3- endometriosis, adenomyosis, myometrial tumors- sgd | Parasitic infections: Neurocysticercosis, free-living Amoeba infection | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | path practical tb intestine, tb node cytology - sgd | |
09-08-24 | Friday | CP | CP | CP | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | PA 30.4 ovarian tumors (lecture) | Microbiology | |
10-08-24 | Saturday | holiday | |||||||
11-08-24 | Sunday | holiday | |||||||
12-08-24 | Monday | CP | CP | CP | OG 16.1 Post partum haemorrhage diagnosis and management | Parasitic infections: Toxoplasmosis | PH 3.1 PW- SGD1/ Practical | PH 3.1 PW- SGD1/ Practical | |
13-08-24 | Tuesday | CP | CP | CP | PH 1.37 Pituitary hormones (L1) | PA 30.5 gestational trophoblastic tumors(SGD) | Lunch | Fungal infections: Cryptococcal meningitis | UTI: Enterobacteriaceae, Enterococcus and others |
14-08-24 | Wednesday | CP | CP | CP | CM 6.3 TEST OF SIGNIFICANCE | CM 6.3 TEST OF SIGNIFICANCE | Internal assessment 6 | PA30.2,30.9 endometrial tumors- integrated session | |
15-08-24 | Thursday | holiday | |||||||
16-08-24 | Friday | CP | CP | CP | PH 1.36 Drugs used in DM (L1) | PH 1.36 Drugs used in DM (L1) | PA 31.1,31.4 benign lesion breast, gynecomastia- SGD | Microbiology | |
17-08-24 | Saturday | AETCOM - sur | BPH management | FM3.18 Virginity | peripheral smear examination, interpretation -SGD | peripheral smear examination, interpretation -SGD | Lunch | PH 1.38 Corticosteroids (L1) | pandemic-cm |
18-08-24 | Sunday | holiday | |||||||
19-08-24 | Monday | CP | CP | CP | SU 12.1 Enumerate the causes and consequences of malnutrition in the surgical patient | UTI -Viral (BK virus), parasitic (Schistosoma haematobium) and fungal infections | PH 3.2 PA SGD1/ Practical | PH 3.2 PA SGD1/ Practical | |
20-08-24 | Tuesday | CP | CP | CP | PH 1.36 Osteoporosis (SGD1/Theory) | PA 31.2 Carcinoma breast lecture | Lunch | Ulcerative Genital Infections Syphilis, LGV | Granuloma inguinale,Soft Chancre,HSV2 |
21-08-24 | Wednesday | CP | CP | CP | ICDS | FM3.19 Pregnancy and Delivery 1 | PA 32.1,32.2,32.3- goiter, graves disease, thyroiditis- SDL | Fibroadenoma, carcinoma breast, (SGD- practical) | |
22-08-24 | Thursday | CP | CP | CP | PATH thyroid neoplasms -lecture | Gonorrhoea,NGU | PH 1.37 Androgens & Anti androgens (L1) | colloid goiter , papillary carcinoma, hashimoto thyroiditis-PATH practical,SGD | |
23-08-24 | Friday | CP | CP | CP | PH 1.37 Estrogens & Progestins (SGD1/Theory) | PH 1.37 Estrogens & Progestins (SGD1/Theory) | PA 32.4 diabetes mellitus SGD | Fungal culture-SGD | |
24-08-24 | Saturday | yoga | OG 14.1 Fetal skull and maternal pelvis | FM3.20 Pregnancy and Delivery 2 | INTERNAL ASSESSMENT | INTERNAL ASSESSMENT | LUNCh | pandemic - micro | sports |
25-08-24 | Sunday | holiday | |||||||
26-08-24 | Monday | holiday | |||||||
27-08-24 | Tuesday | CP | CP | CP | PH 1.41 Uterine stimulants & tocolytics (SGD1/Theory) | PA 32.9 MEN, adrenal neoplasms, pheochromocytoma - lecture | Lunch | Trichomoniasis,Bacterial vaginosis and Vaginal candidiasis | Ocular,Ear, Nose infections |
28-08-24 | Wednesday | CP | CP | CP | INTERNAL ASSESSMENT III | INTERNAL ASSESSMENT III | PA32.5,32.8-cushings syndrome, adrenal insufficiency SDL- | VIVA 4 and 5 | |
29-08-24 | Thursday | CP | CP | CP | Benign lesions of skin -SGD pathology | Congenital infections TORCH complex, Zika virus | LUNCH | PH 1.40 Drugs for Infertility(L1) | osteosarcoma, osteoclastoma, osteochondroma -SGD pathology practical |
30-08-24 | Friday | CP | CP | CP | PH 1.36 Thyroid and Antithyroid drugs (L1) | PH 1.36 Thyroid and Antithyroid drugs (L1) | PA 34.1,34.2,34.3Malignant skin tumors- SGD | Fungal culture | |
31-08-24 | Saturday | AETCOM - OG | OG 19.1 Physiology of Peurperium | FM3.21 Pregnancy and Delivery 3 | microbiology | PH 1.40 Drugs for erectile dysfunction (L1) | PH 2.6 AETCOM- Bioethics | PH 2.6 AETCOM- Bioethics | |
01-09-24 | Sunday | holiday | |||||||
02-09-24 | Monday | CP | CP | PCT 2 | PCT 2 | PCT 2 | PCT 2 | PCT 2 | PCT 2 |
03-09-24 | Tuesday | CP | CP | PCT 2 | PA 33.1,33.4- Metabolic diseases of bone-SGD | PCT 2 | PCT 2 | PCT 2 | PCT 2 |
04-09-24 | Wednesday | CP | CP | PCT 2 | PCT 2 | PCT 2 | PCT 2 | PA 33.2- BONE TUMOR-Integrated session | VIVA 6 |
05-09-24 | Thursday | CP | CP | PCT 2 | PA 33.5 Arthritis-SGD | PCT 2 | PCT 2 | PCT 2 | Hodgkin lymphoma, Secondary carcinomatous deposits, TB nodes-SGD Practical |
06-09-24 | Friday | CP | CP | PCT 2 | PCT 2 | PCT 2 | PCT 2 | SA 33.3 Soft tissue tumors-SGD | PCT 2 |
07-09-24 | Saturday | yoga | surgery theory | PCT 2 | PCT 2 | PCT 2 | PCT 2 | PCT 2 | PCT 2 |
08-09-24 | Sunday | holiday | |||||||
09-09-24 | Monday | CP | CP | CP | OG 21.1 Methods of Contraception | Oncogenic virus HPV,Kaposi,HTLV,EBV,HEP B,C | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | |
10-09-24 | Tuesday | CP | CP | CP | PH 1.39 Drugs used for Contraception (SGD1/Theory) | IA7 | Lunch | Zoonotic infection-Plague,Tularemia, Bite wound infection | Opportunistic and transplant infection |
11-09-24 | Wednesday | CP | CP | CP | CM 8.5 IMPORTANT PUBLIC HEALTH EVENTS | Impotence and Sterility 2 FM3.23 | LUNCH | PA 13.1,13.3,14.1,14.2- Iron def anemia-L | PA 15.1,15.2,15.3,15.4- Megaloblastic anemia-Int session |
12-09-24 | Thursday | CP | CP | CP | PA 16.1,16.2,16.4,16.3- Hemolytic anemia -Sickle cell anemia, Thalassemia-SGD | Emerging & re emerging infections | PH 1.39 Drugs used for Contraception (SGD1/Theory) | IDA, Megaloblastic anemia- Practical | |
13-09-24 | Friday | CP | CP | CP | PH 1.52 Toxicology Charts (SGD1/ Practical) | PH 1.52 Toxicology Charts (SGD1/ Practical) | PA 18.2- AML, ALL-L | OSPE | |
14-09-24 | Saturday | holiday | |||||||
15-09-24 | Sunday | holiday | |||||||
16-09-24 | Monday | holiday | |||||||
17-09-24 | Tuesday | PTA | PTA | PTA | PTA | PA 18.1,18.2 CML,CLL-L | PTA | PTA | PTA |
18-09-24 | Wednesday | CP | CP | CP | CM 6.2,6.3,6.4 DESCRIPTIVE STATISTICS I | CM 6.2,6.3,6.4 DESCRIPTIVE STATISTICS I | PA 17.1,17.2- Hemolytic anemia, aplastic anemia- SGD | PA 21.1-21.4-DIC,ITP,TTP,HUS | |
19-09-24 | Thursday | CP | CP | CP | PA 31.2 CA BREAST | Healthcare Associated infection VAP,CAUTI | LUNCH | PH 5.2 DRUG THERAPY, STORAGE | KALEIDOSCOPE-CME |
20-09-24 | Friday | CP | CP | CP | PH 5.1 Empathy, Ethics | PH 5.1 Empathy, Ethics | KALEIDOSCOPE-CME | OSPE | |
21-09-24 | Saturday | PANDEMIC MODULE 2.5 | IM13.3 INFECTION AND CANCER RELATIONSHIP | FM3.24 Impotence and Sterility 3 | KALEIDOSCOPE-CME | KALEIDOSCOPE-CME | Lunch | PH 5.2 DRUG THERAPY, STORAGE | pandemic - cm |
22-09-24 | Sunday | holiday | |||||||
23-09-24 | Monday | CP | CP | CP | OG17.1 PHYSIOLOGY OF LACTATION | Healthcare Associated infection CRBSI,SSI | PH 2.1 Dosage forms DOAP 1/ Practical | PH 2.1 Dosage forms DOAP 1/ Practical | |
24-09-24 | Tuesday | CP | CP | CP | PH 5.3 ADHERENCE | PA 16.4- Bone marrow aspiration/biopsy-SGD | Lunch | Confidentiality pertaining to patient's identity in lab result | IPC - Standard precautions |
25-09-24 | Wednesday | CP | CP | CP | CM 6.2,6.3,6.4 DESCRIPTIVE STATISTICS II | FM3.25 Impotence and Sterility 4 | HB ESTIMATION, BLOOD GROUPING-THEORY-L | PA 19.6,21.2,21.5-VIT K ,SPLENOMEGALY, HEMOPHILIA-SDL | |
26-09-24 | Thursday | CP | CP | CP | PA 20.1 PLASMA CELL DISORDERS-SGD | IPC - Transmission based precautions | PH 5.3 ADHERENCE | HB ESTIMATION, BLOOD GROUPING-PRACTICAL-SGD | |
27-09-24 | Friday | CP | CP | CP | PH 5.4 COST AND COMPLAINCE | PH 5.5 DEPENDANCE | PA 19.4,19.5-HODGKIN, NONHODGKIN LYMPHOMA-SGD | SPOTTERS | |
28-09-24 | Saturday | yoga | OG 22.1 Leucorrhoea diagnosis and management | FM3.26 Impotence and Sterility 5 | INTERNAL ASSESSMENT | INTERNAL ASSESSMENT | LUNCh | pandemic- micro | sports |
29-09-24 | Sunday | holiday | |||||||
30-09-24 | Monday | CP | CP | CP | IM13.1 EPIDEMIOLOGY AND INHERITED AND MODIFIABLE RISK OF COMMON CANCER | Transfusion Transmissable infections | PH 3.7Essential medicines (SGD/PRACTICAL) | PH 3.7Essential medicines (SGD/PRACTICAL) | |
01-10-24 | Tuesday | CP | CP | CP | PH 1.54 Vaccines and antisera(SDL) | PA 22.4 ENUMERATE BLOOD COMPONENTS -SDL | Lunch | Vaccine preventable diseases | Laboratory-acquired Infection |
02-10-24 | Wednesday | holiday | |||||||
03-10-24 | Thursday | CP | CP | CP | PA 22.4 BLOOD COMPONENTS & ITS CLINICAL USE -SGD | Hospital Infection Control Committee | LUNCH | PH 1.57 Drugs used in skin disorders (SDL) | PATH PRACTICALS - HEMOGLOBIN ESTIMATION |
04-10-24 | Friday | CP | CP | CP | PH 1.55 National health programmes (SGD1/Theory) | PH 1.55 National health programmes (SGD1/Theory) | PA 22.4 BLOOD COMPONENTS & ITS CLINICAL USE -SGD | SPOTTERS | |
05-10-24 | Saturday | yoga | SU 12.2 Describe and discuss the methods of estimation and replacement of the fluid and electrolyte requirements in the surgical patient | FM3.27 Abortion 1 | PA 22.6. TRANSFUSION REACTION (SGD) | Pharmacology IA-8 CNS | PH 2.6 AETCOM- Bioethics | PH 2.6 AETCOM- Bioethics | |
06-10-24 | Sunday | holiday | |||||||
07-10-24 | Monday | CP | CP | CP | IM14.1 DEFINE AND MEASURE OBESITY | CSSD | PH 2.3 IV Drip setting DOAP1/Practical | PH 2.3 IV Drip setting DOAP1/Practical | |
08-10-24 | Tuesday | CP | CP | CP | 1.64 Drug Development & GCP ( L1) | PA 22.5 INFECTIONS TRANSMITTED BY BLOOD TRANSFUSION (SGD) | Lunch | Antimicrobial Stewardship-Integrated class | Antimicrobial Stewardship-Integrated class |
09-10-24 | Wednesday | CP | CP | CP | CM 6.2,6.3,6.4 INFERENTIAL STATISTICS I | Abortion 2 FM3.28 | LUNCH | PA 22.6. STEPS IN INVESTIGATION OF TRANSFUSION REACTION (SGD) | PA 22.7 ENUMERATE INDICATIONS FOR AUTOLOGOUS TRANSFUSION (SGD) |
10-10-24 | Thursday | CP | CP | CP | PA 22.7 PRINCIPLES & PROCEDURE - AUTOLOGOUS TRANSFUSION (SGD) | ENVIRONMENTAL SURVEILLANCE-Bacteriology of Air,Water and Milk | 1.63 Drug Regulations( L1) | PA 22.7 PRINCIPLES & PROCEDURE - AUTOLOGOUS TRANSFUSION (SGD) | |
11-10-24 | Friday | holiday | |||||||
12-10-24 | Saturday | holiday | |||||||
13-10-24 | Sunday | holiday | |||||||
14-10-24 | Monday | CP | CP | CP | OG 27.1 Sexually transmitted diseases | Seminar | PH 3.7Essential medicines (SGD/PRACTICAL) | PH 3.7Essential medicines (SGD/PRACTICAL) | |
15-10-24 | Tuesday | CP | CP | CP | PH 5.6 OTC- SGD 1 | PA 20.1 - PLASMA CELL MYELOMA - DOAP | Lunch | Seminar | Seminar |
16-10-24 | Wednesday | CP | CP | CP | CM 6.2,6.3,6.4 INFERENTIAL STATISTICS II | CM 6.2,6.3,6.4 INFERENTIAL STATISTICS II | PA 22.1 CLASSIFY & DESCRIBE BLOOD GROUP SYSTEMS -SDL | PA 16.7 CROSS MATCHING TECHNIQUE -L | |
17-10-24 | Thursday | CP | CP | CP | PATH PRACTICALS - HEMOGLOBIN ESTIMATION | Practicals IA | LUNCH | PH 5.6 OTC- SGD 1 | PATH PRACTICALS - BLOOD GROUPING & TYPING (SGD) |
18-10-24 | Friday | CP | CP | CP | PH 5.7 Communication skills – Legal and ethical aspects (SGD1/ Practical) | PH 5.7 Communication skills – Legal and ethical aspects (SGD1/ Practical) | PATH PRACTICALS - HEMOGLOBIN ESTIMATION | Practicals IA | |
19-10-24 | Saturday | AETCOM - sur | blood disorders mgt | FM3.29 Infanticide | PATH PRACTICALS - PERIPHERAL SMEAR - INTERPRETATION | Pathology IA 9 SP | Lunch | PH 3.6 Interaction with Pharma Representative | pandemic-cm |
20-10-24 | Sunday | holiday | |||||||
21-10-24 | Monday | CP | CP | CP | SU 12.3 Discuss the nutritional requirements of surgical patients, the methods of providing nutritional support and their complications | Microbiology | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | |
22-10-24 | Tuesday | CP | CP | CP | PH 4.1 ROUTES OF ADMINISTRATION (DOAP 1/ Practical) | PATH PRACTICALS - PERIPHERAL SMEAR - INTERPRETATION | Lunch | Microbiology | Microbiology |
23-10-24 | Wednesday | CP | CP | CP | CM 3.1Plastic pollution(Seminar) | FM3.30 FM3.31 FM3.33 Medicolegal aspect of injury & Medical Ethics and Law | PATH PRACTICALS - PERIPHERAL SMEAR - INTERPRETATION | PATH PRACTICALS - HPE REQUEST WRITING | |
24-10-24 | Thursday | CP | CP | CP | PATH PRACTICALS - FNAC REQUEST WRITING | Microbiology | PH 3.8 Drug counselling | PATH PRACTICALS - PERIPHERAL SMEAR DEMONSTRATION | |
25-10-24 | Friday | CP | CP | CP | PH 4.2 CAL (SGD1/ Practical) | PH 4.2 CAL (SGD1/ Practical) | PA 23.3 - INTERPRET LIVER FUNCTION TESTS | Microbiology | |
26-10-24 | Saturday | yoga | OG 23.1 PHYSIOLOGY OF PUBERTY | FM3.32 Legal Procedure | Microbiology | Microbiology | LUNCh | pandemic-micro | sports |
27-10-24 | Sunday | holiday | |||||||
28-10-24 | Monday | CP | CP | CP | SU 11.6 Describe Principles of safe General Surgery | Microbiology | PH 3.2 PA SGD1/ Practical | PH 3.2 PA SGD1/ Practical | |
29-10-24 | Tuesday | CP | CP | CP | PH 3.8 Drug counselling | PA 23.3 - INTERPRET LIVER FUNCTION TESTS | Lunch | Microbiology | Microbiology |
30-10-24 | Wednesday | CP | CP | CP | CM 8.1 Disinfection(L) | Disinfection(L) | PATH PRACTICALS - urine examinationDEMONSTRATION | Pathology | |
31-10-24 | Thursday | holiday | |||||||
01-11-24 | Friday | CP | CP | CP | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment |
02-11-24 | Saturday | yoga | SU 11. 4 Enumerate the indications and principles of day care General Surgery | AUTOPSY | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment |
03-11-24 | Sunday | holiday | |||||||
04-11-24 | Monday | CP | CP | CP | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment |
05-11-24 | Tuesday | CP | CP | CP | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment |
06-11-24 | Wednesday | CP | CP | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment | |
07-11-24 | Thursday | CP | CP | CP | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment | theory summative assessment |
08-11-24 | Friday | CP | CP | CP | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment |
09-11-24 | Saturday | holiday | |||||||
10-11-24 | Sunday | holiday | |||||||
11-11-24 | Monday | CP | CP | CP | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment |
12-11-24 | Tuesday | CP | IM15.1 DESCRIBE AND DISCUSS THE ETIOLOGY OF UGI AND LGI BLEED | CP | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment |
13-11-24 | Wednesday | CP | CP | CP | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment | practical summative assessment |
14-11-24 | Thursday | CP | CP | CP | |||||
15-11-24 | Friday | CP | CP | CP | OG 24.1 Abnormal uterine bleeding -definition and classification | PH 3.8 Drug counselling | PATH PRACTICALS - urine examinationDEMONSTRATION | pandemic - cm | |
16-11-24 | Saturday | PANDEMIC MODULE 2.5 | IBS,IBD | AUTOPSY | PATH PRACTICALS - SKILL CERTIFICATION | Lunch | PH AETCOM | PH AETCOM | |
17-11-24 | Sunday | holiday | |||||||
18-11-24 | Monday | CP | OG 18.1 assessment of new born | SU 9.2 Biological basis for early detection of cancer and multidisciplinary approach in management of cancer | Microbiology | PH 3.3 DPL- SGD1/ Practical | PH 3.3 DPL- SGD1/ Practical | ||
19-11-24 | Tuesday | CP | SU 5.2 Differentiate the various types of wounds, plan and observe management of wounds. | CP | PH 2.2ORS (SGD1/ Practical) | pathology | Lunch | Microbiology | Microbiology |
20-11-24 | Wednesday | CP | CP | CP | CM 3.1 Radiation hazards(Seminar) | FM3.30 FM3.31 FM3.33 Medicolegal aspect of injury & Medical Ethics and Law | Pathology | Pathology | |
21-11-24 | Thursday | CP | SUMMATIVE ASSESSMENT 1 | CP | pathology | Microbiology | PH 2.2ORS (SGD1/ Practical) | pathology | |
22-11-24 | Friday | CP | CP | CP | PH 2.1 Dosage forms DOAP 1/ Practical | PH 2.1 Dosage forms DOAP 1/ Practical | pathology | Microbiology | |
23-11-24 | Saturday | yoga | OG 32.1 Physiology of menopause | AUTOPSY | Microbiology | Microbiology | LUNCh | pandemic- micro | sports |
24-11-24 | Sunday | holiday | |||||||
25-11-24 | Monday | CP | CP | CP | SUMMATIVE ASSESSMENT 2 | Microbiology | PH 2.1 Dosage forms DOAP 1/ Practical | PH 2.1 Dosage forms DOAP 1/ Practical | |
26-11-24 | Tuesday | CP | CP | CP | PH 2.1 Dosage forms DOAP 1/ Practical | pathology | Lunch | Microbiology | Microbiology |
27-11-24 | Wednesday | CP | CP | CP | INTERNAL ASSESSMENT-IV | INTERNAL ASSESSMENT-IV | Pathology | Pathology | |
28-11-24 | Thursday | CP | CP | CP | pathology | Microbiology | LUNCH | PH 2.1 Dosage forms DOAP 1/ Practical | pathology |
29-11-24 | Friday | CP | CP | CP | PH 3.5 P-drug (SGD1/ Practical)) | PH 3.5 P-drug (SGD1/ Practical)) | pathology | Microbiology | |
30-11-24 | Saturday | yoga | CP | AUTOPSY | Microbiology | PH 3.4 ADR REPORTING | MI AETCOM | MI AETCOM |